WO2016104617A1 - キノリン誘導体 - Google Patents
キノリン誘導体 Download PDFInfo
- Publication number
- WO2016104617A1 WO2016104617A1 PCT/JP2015/086050 JP2015086050W WO2016104617A1 WO 2016104617 A1 WO2016104617 A1 WO 2016104617A1 JP 2015086050 W JP2015086050 W JP 2015086050W WO 2016104617 A1 WO2016104617 A1 WO 2016104617A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl group
- compound
- hydrogen atom
- optionally substituted
- Prior art date
Links
- MRQPULYKJYONQM-UHFFFAOYSA-N CC1(CC1)N(C=CC=C1C(NC)=O)C1=O Chemical compound CC1(CC1)N(C=CC=C1C(NC)=O)C1=O MRQPULYKJYONQM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Definitions
- the present invention relates to general formula (I) (Wherein all symbols have the same meaning as described below), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof (hereinafter abbreviated as a compound of the present invention). There is.)
- Axl (also known as UFO, ARK, Tyro7) is a receptor tyrosine kinase belonging to the TAM family (Axl, Mer and Tyro3) cloned from tumor cells.
- Gas6 growth-arrest-specific protein 6
- Axl activated by the binding of Gas6 transmits a signal via phosphorylation. Since the signal activates the Erk1 / 2 pathway and the PI3K / Akt pathway, the activation of Axl is known to be involved in pathologies such as cancer, immune system diseases, cardiovascular diseases (non-patented). Reference 1).
- Axl expression is involved in breast cancer metastasis and prognosis (see Non-Patent Document 2), and Axl is acute myeloid leukemia (AML). It is known that it is involved in the pathological condition of (acute myeloid leukemia) (see Non-Patent Document 3). Therefore, compounds that inhibit Axl activation are considered useful for the treatment of various cancers, immune system diseases, and cardiovascular diseases.
- the formula (C) Is known as a prophylactic and / or therapeutic agent for amyotrophic lateral sclerosis (ALS) (see Patent Document 3).
- R D represents It represents like; T D represents phenyl and the like; Z D represents N or CR 7D; W D represents a substituted or unsubstituted phenyl, a nitrogen-containing heteroaryl, etc. 6-membered substituted or unsubstituted;
- X D Represents O, S, S ( ⁇ O), etc .;
- Y D represents —NR aD C ( ⁇ O) — (CR 3D R 4D ) p —, etc .;
- R aD represents a hydrogen atom, an alkyl group or the like.
- R 1D is J 2D represents O or CR 4aD R 4aD ;
- Q D represents a 1 to 5 membered saturated or partially unsaturated alkyl chain or the like;
- R 1D may be substituted May be condensed with phenyl or an optionally substituted 5- to 6-membered heterocycle;
- R 3D and R 4D each independently represents a hydrogen atom, an alkyl, an aryl group, or the like; is R 4aD absent? , Represents a hydrogen atom, a halogen atom, etc. (however, the definition of each group was excised) ) Is known to be a c-Met inhibitor (see Patent Document 4).
- R 1E, R 2E and R 4E are independently H, F, Cl, Br, I, CN, represent OR 10E, C1-C12 alkyl or the like;
- L E is C3-C12 carbocycle,
- C6 R 5E represents —C ( ⁇ Y E ) R 13E , —C ( ⁇ Y E ) R 10E R 13E , —NR 10E C ( ⁇ Y E ) R 13E, etc .;
- R 10E Represents H, C1-C12 alkyl, C3-C12 carbocycle, C2-C20 heterocycle, etc .;
- R 13E represents H, C1-C6 alkyl, etc .;
- Y E represents O or S (provided that each The definition of the group was excised.))
- Is known to be a c-Met inhibitor see Patent Document 5).
- An object of the present invention is to find a compound having Axl inhibitory activity useful for the treatment of cancer such as AML and provide it as a pharmaceutical product.
- the present inventors have intensively studied to find a compound that strongly inhibits Axl. As a result, they have surprisingly found that the compound of the present invention has a potent Axl inhibitory activity. Was completed.
- R 1 is (1) a C1-8 alkyl group optionally substituted with 1 to 5 R 11 , and (2) C3-7 optionally substituted with 1 to 5 R 12 Or (3) a 4 to 7-membered hetero ring optionally substituted with 1 to 5 R 13 ,
- R 1 is a branched chain alkyl group
- the C1-3 alkyl groups branched from the same carbon atom together form a C3-7 saturated carbocyclic ring.
- R 2 is (1) 1-5 which may be substituted C1 ⁇ have 8 alkyl group R 21, (2) 1-5 optionally substituted C2 ⁇ 8 alkenyl group R 22, ( 3) C2-8 alkynyl group optionally substituted with 1 to 5 R 23 , (4) —OR 24 group, (5) C3-7 optionally substituted with 1 to 5 R 25 (6) a 4 to 7-membered hetero ring optionally substituted with 1 to 5 R 26 , (7) a halogen atom, (8) a C (O) R 27 group, or (9) Represents a C (O) NR 28 R 29 group,
- m is 2 or more
- R 2 is on an adjacent carbon atom, and R 2 may be substituted with an amino group or a C1-3 alkyl group, or may be substituted with an amino group
- R 2 bonded to an adjacent carbon atom is taken together with the carbon atom to form a 5- to 7-membered cycl
- R 1 represents a C1-3 alkyl group
- R 3 represents (1) a C1-4 alkyl group, (2) a halogen atom, (3) a C1-4 haloalkyl group, or (4) an —OR 31 group
- R 4 is (1) a C1-4 alkoxy group, (2) a C1-4 haloalkyl group, (3) an —OR 41 group, (4) a C1-4 alkyl group, (5) a C2-4 alkenyloxy group, or ( 6) represents a C2-4 alkynyloxy group
- R 11 is (1) —OR 101 group, (2) SO 2 R 102 group, (3) NR 103 R 104 group, or (4) C 3-7 optionally substituted with 1 to 3 halogen atoms.
- R 12 represents (1) a C1-4 alkyl group optionally substituted with an amino group, (2) a C1-4 haloalkyl group, (3) a halogen atom
- R 13 represents (1) a C1-4 alkyl group optionally substituted with an amino group, (2) a C1-4 haloalkyl group, (3) a halogen atom
- R 101 represents (1) a hydrogen atom, or (2) a C1-4 alkyl group
- R 102 represents (1) a hydrogen atom, or (2) a C1-4 alkyl group
- R 103 and R 104 each independently represent (1) a hydrogen atom, or (2) a C1-4 alkyl group
- R 20 represents (1) a C1-4 alkyl group, (2) a halogen atom, (3) a C1-4 haloalkyl group, (4) an oxo group, (5) an —OR 201 group, (6) a COOR 205 group, (7 ) NR 206 R 207 group, or (8) COR 208 group, wherein when two R
- R 2 is (1) a C1-8 alkyl group optionally substituted with 1 to 5 R 21 s , and (2) a C2-8 alkenyl optionally substituted with 1 to 5 R 22 s.
- composition according to the above [7], which is a cancer cell metastasis inhibitor [13] A method comprising administering to a mammal an effective amount of a compound represented by the general formula (I) described in [1], a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof.
- a method of preventing and / or treating an Axl related disease [14] The compound represented by the general formula (I), the salt, the solvate, the N-oxide, or the prodrug thereof according to [1] for the prevention and / or treatment of an Axl-related disease, And [15] A compound represented by the general formula (I), a salt thereof, a solvate thereof, an N-oxide thereof, or them for producing a preventive and / or therapeutic agent for an Axl-related disease Related to the use of prodrugs.
- the compound of the present invention has a strong Axl inhibitory activity and has an Axl selective inhibitory activity against a specific kinase, and also has a reduced CYP inhibitory action. It is useful as a therapeutic agent for acute myeloid leukemia with little concern.
- the halogen atom means fluorine, chlorine, bromine or iodine.
- the C1-8 alkyl group includes a linear or branched C1-8 alkyl group.
- methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl examples include isobutyl, sec-butyl, tert-butyl, and isomers thereof.
- the C1-4 alkyl group includes linear or branched C1-4 alkyl groups such as methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl, tert-butyl, and the like.
- a butyl group is mentioned.
- the C1-3 alkyl group includes a linear or branched C1-3 alkyl group, and examples thereof include a methyl, ethyl, propyl, and isopropyl group.
- the C1-4 haloalkyl group means, for example, a fluoromethyl group, a chloromethyl group, a bromomethyl group, an iodomethyl group, a difluoromethyl group, a trifluoromethyl group, a 1-fluoroethyl group, a 2-fluoroethyl group, 2 Means chloroethyl, pentafluoroethyl, 1-fluoropropyl, 2-chloropropyl, 3-fluoropropyl, 3-chloropropyl, 4,4,4-trifluorobutyl, 4-bromobutyl To do.
- the C2-8 alkenyl group means, for example, vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl groups, and isomers thereof.
- the C2-4 alkenyl group includes a linear or branched C2-4 alkenyl group, and examples thereof include ethenyl, propenyl, butenyl, and isomers thereof.
- the C2-3 alkenyl group includes a linear or branched C2-3 alkenyl group, and examples thereof include ethenyl, propenyl, and isomers thereof.
- the C2-8 alkynyl group means, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl group, and isomers thereof.
- the C2-4 alkynyl group includes a linear or branched C2-4 alkynyl group, and examples thereof include ethynyl, propynyl, butynyl, and isomers thereof.
- the C1-8 alkylene group includes linear or branched C2-8 alkylene groups such as methylene, ethylene, propylene, butylene, pentylene, hexalene, heptalene, octalene, and the like. Means an isomer of
- the C2-8 alkenylene group means ethynylene, propynylene, butenylene, pentenylene, hexenylene, hebutenylene, octenylene, and isomers thereof.
- the C1-4 alkoxy group includes, for example, a methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, or tert-butoxy group.
- the C2-4 alkenyloxy group means, for example, vinyloxy, propenyloxy, butenyloxy, and isomers thereof.
- the C2-4 alkynyloxy group means, for example, ethynyloxy, propynyloxy, butynyloxy, and isomers thereof.
- the C3-7 carbocycle means a C3-7 monocyclic carbocycle, a carbocycle in which part or all of which may be saturated, such as cyclopropane, cyclobutane, cyclopentane. , Cyclohexane, cycloheptane, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclobutadiene, cyclopentadiene, cyclohexadiene, cycloheptadiene, or a benzene ring.
- the C5-7 carbocycle means a C5-7 monocyclic carbocycle, a carbocycle in which part or all of which may be saturated, such as cyclopentane, cyclohexane, cycloheptane. , Cyclopentene, cyclohexene, cycloheptene, cyclopentadiene, cyclohexadiene, cycloheptadiene, or a benzene ring.
- examples of the C3-7 saturated carbocycle include cyclopropane, cyclobutane, cyclopentane, cyclohexane and cycloheptane.
- the 4- to 10-membered heterocycle is a partially or fully saturated 4- to 10-membered monocycle containing 1 to 5 heteroatoms selected from oxygen, nitrogen and sulfur atoms. Or a bicyclic heterocycle.
- the 4- to 7-membered heterocycle is a partially or fully saturated 4- to 7-membered monocycle containing 1 to 5 heteroatoms selected from oxygen, nitrogen and sulfur atoms.
- Heterocycle For example, azetidine, pyrroline, pyrrolidine, imidazoline, imidazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, pyrazoline, pyrazolidine, dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, perhydropyrimidine, Dihydropyridazine, tetrahydropyridazine, perhydropyridazine, dihydroazepine, tetrahydroazepine, perhydroazepine, dihydrodiazepine, te
- the 5- to 7-membered cyclic group means a C5-C7 carbocyclic ring and a 5- to 7-membered heterocyclic ring.
- the C5-7 carbocycle has the same meaning as described above, and the 5- to 7-membered heterocycle includes a 5- to 7-membered unsaturated heterocycle and a 5- to 7-membered saturated heterocycle.
- Examples of the 5- to 7-membered heterocycle include pyrroline, pyrrolidine, imidazoline, imidazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, pyrazoline, pyrazolidine, dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, dihydropyrimidine , Tetrahydropyrimidine, perhydropyrimidine, dihydropyridazine, tetrahydropyridazine, perhydropyridazine, dihydroazepine, tetrahydroazepine, perhydroazepine, dihydrodiazepine, tetrahydrodiazepine, perhydrodiazepine, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydro Pyran, dihydrooxepin
- R 2 is adjacent and R 2 is a substituted 3 ⁇ C1 may be an alkyl group with an amino group or an optionally substituted C2 ⁇ 3 alkenyl group with an amino group
- R 2 bonded to an adjacent carbon atom may form a 5- to 7-membered cyclic group which may be substituted with 1 to 3 R 20 together with the carbon atom.
- I is a partial structure of the following general formula (I) (Wherein all symbols have the same meaning as described above), for example, when a plurality of R 2 are alkyl groups as shown in the above formula, together with adjacent carbon atoms, (Wherein all symbols have the same meaning as described above) means that a 5- to 7-membered cyclic group such as a cyclohexane ring is formed.
- R 1 is (1) a C1-8 alkyl group optionally substituted with 1 to 5 R 11 s , or (2) optionally substituted with 1 to 5 R 12s.
- a C3-7 carbocycle is preferred, and benzene is preferred as the C3-7 carbocycle.
- R 2 is a C1-8 alkyl group optionally substituted with 1 to 5 R 21 , a C2-8 alkenyl group optionally substituted with 1 to 5 R 22 , 1 to five optionally substituted C2 ⁇ 8 alkynyl group R 23, a halogen atom or C (O) R 27 group, are preferred.
- L is preferably —O—, —NH—, or —C (O) —, more preferably —O—.
- ring 1 is preferably benzene or pyridine.
- the two bonds in ring 1 are preferably bonded to the para position.
- the compound described in the Examples is preferable as the preferable compound, and (1) 5-acetyl-N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -6-methyl-2-oxo-1-phenyl-1,2-dihydro-3-pyridinecarboxamide, (2) N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -3,8-Dioxo-2-phenyl-2,3,5,6,7,8-hexahydro-4-isoquinolinecarboxamide, (3) N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) ) Oxy] -2-pyridinyl ⁇ -2,5-dioxo-1-phenyl-2,5,6,7,8,9-hexahydro-1H-pyrido [3,2-c] azepine-3-car
- alkyl groups include straight chain and branched chain.
- geometric isomers in double bonds, rings and condensed rings E-form, Z-form, cis-form, trans-form
- optical isomers due to the presence of asymmetric carbon atoms, etc. R, S-form, ⁇ , ⁇ configuration, Enantiomers, diastereomers
- optically active substances having optical activity D, L, d, l form
- polar forms high polar form, low polar form
- optical isomers in the present invention may include not only 100% pure but also other optical isomers of less than 50%.
- the compound represented by the general formula (I) is converted into a corresponding salt by a known method.
- the salt is preferably water-soluble.
- the salt is preferably a pharmaceutically acceptable salt. Suitable salts include alkali metal (potassium, sodium, etc.) salts, alkaline earth metal (calcium, magnesium, etc.) salts, ammonium salts, pharmaceutically acceptable organic amines (tetramethylammonium, triethylamine, methylamine).
- inorganic Acid salt hydroochloride, hydrobromide, hydroiodide,
- the compound represented by the general formula (I) and a salt thereof can be converted into a solvate.
- the solvate is preferably low toxic and water soluble.
- Suitable solvates include, for example, solvates with water and alcohol solvents (for example, ethanol).
- the N-oxide form of the compound represented by the general formula (I) represents an oxidized nitrogen atom of the compound represented by the general formula (I). Further, the N-oxide form of the compound represented by the general formula (I) may further be an alkali (earth) metal salt, ammonium salt, organic amine salt, or acid adduct salt.
- the prodrug of the compound represented by the general formula (I) refers to a compound that is converted into a compound represented by the general formula (I) by a reaction with an enzyme, gastric acid or the like in a living body.
- a prodrug of the compound represented by the general formula (I) when the compound represented by the general formula (I) has a hydroxyl group, a compound in which the hydroxyl group is acylated, alkylated, phosphorylated or borated (for example, Compound in which the hydroxyl group of the compound of the present invention is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alanylated, dimethylaminomethylcarbonylated, etc.); carboxyl group of the compound represented by the general formula (I) Esterified, amidated compounds (eg, the carboxyl group of the compound represented by the general formula (I) is ethyl esterified, iso
- the prodrug of the compound represented by the general formula (I) may be either a hydrate or a non-hydrate.
- prodrugs of the compounds represented by the general formula (I) are represented by the general formula under physiological conditions as described in Yodogawa Shoten 1990, “Drug Development”, Vol. 7, “Molecular Design”, pages 163-198. It may be changed to the compound represented by (I).
- the compound represented by the general formula (I) is an isotope (for example, 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 35 S, 18 F, 36 Cl, 123 I, 125 I, etc.).
- the compound of the present invention can be obtained by a known method, for example, the method described in Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition (Richard C. Larock, John Wiley & Sons Inc, 1999) or the method shown in the Examples. It can manufacture by improving suitably etc. and using them in combination.
- reaction 1 can be carried out by subjecting the compound represented by general formula (a) and the compound represented by general formula (II) to an aromatic nucleophilic substitution reaction.
- This aromatic nucleophilic substitution reaction is known, for example, organic solvents (chlorobenzene, N, N-dimethyl sulfoxide, N, N-dimethylacetamide, N, N-dimethylformamide, chloroform, dichloromethane, diethyl ether, tetrahydrofuran, methyl t
- the reaction is carried out at 0 to 200 ° C. in the presence of a catalyst (such as 4-dimethylaminopyridine (DMAP)) and in the presence or absence of a base (such as sodium hydride) in butyl ether.
- a catalyst such as 4-dimethylaminopyridine (DMAP)
- DMAP 4-dimethylaminopyridine
- the reaction 2 is carried out using a compound represented by the general formula (b) in an organic solvent (tetrahydrofuran or the like) in a palladium catalyst (tris (dibenzylideneacetone) dipalladium (0) chloroform complex or the like).
- a base lithium bis (trimethylsilyl) amide (LHMDS), potassium bis (trimethylsilyl) amide (KHMDS), sodium bis (trimethylsilyl) amide (NaHMDS), etc.
- a phosphine compound (2-dicyclohexylphosphino-2 Reaction in the presence of ', 6'-dimethoxybiphenyl (S-Phos), tri-tert-butylphosphine (P (t-Bu) 3 ), etc.
- Hydrofluoric acid, hydroiodic acid, sulfuric acid, phosphoric acid, nitric acid, etc. and react at 0 to 150 ° C. It is carried out by.
- the arylamine can be produced according to the method for producing an arylamine described in Organic Letters, Vol. 3, No. 17, pages 2729-2732, 2001.
- reaction 3 can be carried out by subjecting it to an amidation reaction using the compound represented by the general formula (c) and the compound represented by the general formula (d).
- This amidation reaction is known, for example (1) a method using an acid halide, (2) a method using a mixed acid anhydride, (3) A method using a condensing agent is exemplified.
- the method using an acid halide is, for example, using a carboxylic acid in an organic solvent (chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.) or without a solvent and an acid halide agent (oxalyl chloride, thionyl chloride, etc.) and ⁇ 20 C.
- an organic solvent chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.
- an acid halide agent oxalyl chloride, thionyl chloride, etc.
- the resulting acid halide in the presence of a base (pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, diisopropylethylamine, etc.) and an organic solvent (chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.)
- a base pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, diisopropylethylamine, etc.
- an organic solvent chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.
- the obtained acid halide can be reacted with an amine at 0 to 40 ° C. in an organic solvent (dioxane, tetrahydrofuran, etc.) using an aqueous alkali solution (aqueous sodium bicarbonate or sodium hydroxide solution).
- a method using a mixed acid anhydride is, for example, a method in which a carboxylic acid is used in an organic solvent (chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.) or without a solvent, and a base (pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, diisopropyl).
- an organic solvent chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.
- a base pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, diisopropyl
- ethylamine In the presence of ethylamine, etc., it is reacted with an acid halide (pivaloyl chloride, tosyl chloride, mesyl chloride, etc.) or an acid derivative (ethyl chloroformate, isobutyl chloroformate, etc.) at 0 to 40 ° C., and the resulting mixture
- an acid halide pivaloyl chloride, tosyl chloride, mesyl chloride, etc.
- an acid derivative ethyl chloroformate, isobutyl chloroformate, etc.
- the reaction is carried out by reacting the acid anhydride with an amine at 0 to 40 ° C. in an organic solvent (chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.).
- a method using a condensing agent includes, for example, carboxylic acid and amine in an organic solvent (chloroform, dichloromethane, dimethylformamide, diethyl ether, tetrahydrofuran, etc.) or without solvent, with a base (diisopropylethylamine (DIPEA), pyridine , Triethylamine, dimethylaniline, dimethylaminopyridine, etc.) in the presence or absence of a condensing agent (O- (7-aza-1-benzotriazolyl) -N, N, N ′, N′-tetramethyluro Ni hexafluorophosphate (HATU), 1,3-dicyclohexylcarbodiimide (DCC), 1-ethyl-3- [3- (dimethylamino) propyl] carbodiimide (EDC), 1,1′-carbonyldiimidazole (CDI), 2-chloro-1-methylpyridin
- a deprotection reaction when a protecting group is present in the compound represented by each general formula, a deprotection reaction can be performed as necessary.
- This deprotection reaction of the protecting group is known and can be performed by the following method. For example, (1) deprotection reaction by alkaline hydrolysis, (2) deprotection reaction under acidic conditions, (3) deprotection reaction by hydrogenolysis, (4) silyl group deprotection reaction, (5) metal Deprotection reaction to be used, (6) Deprotection reaction using a metal complex, and the like.
- the deprotection reaction by alkali hydrolysis is carried out by using, for example, an alkali metal hydroxide (for example, sodium hydroxide, potassium hydroxide, lithium hydroxide) in an organic solvent (for example, methanol, tetrahydrofuran, dioxane, etc.), Performed at 0 to 40 ° C. using an alkaline earth metal hydroxide (eg, barium hydroxide, calcium hydroxide, etc.) or carbonate (eg, sodium carbonate, potassium carbonate, etc.), an aqueous solution thereof, or a mixture thereof. It is.
- an alkali metal hydroxide for example, sodium hydroxide, potassium hydroxide, lithium hydroxide
- organic solvent for example, methanol, tetrahydrofuran, dioxane, etc.
- an alkaline earth metal hydroxide eg, barium hydroxide, calcium hydroxide, etc.
- carbonate eg, sodium carbonate, potassium carbonate, etc.
- the deprotection reaction under acid conditions is carried out by using, for example, an organic acid (eg, acetic acid, trifluoroacetic acid) in an organic solvent (eg, dichloromethane, chloroform, dioxane, ethyl acetate, methanol, isopropyl alcohol, tetrahydrofuran, anisole, etc.). , Methanesulfonic acid, p-tosylic acid, etc.), or inorganic acids (eg, hydrochloric acid, sulfuric acid, etc.) or mixtures thereof (eg, hydrogen bromide / acetic acid, etc.), the presence of 2,2,2-trifluoroethanol
- an organic acid eg, acetic acid, trifluoroacetic acid
- organic solvent eg, dichloromethane, chloroform, dioxane, ethyl acetate, methanol, isopropyl alcohol, tetrahydrofuran, anisole, etc.
- the deprotection reaction by hydrogenolysis is, for example, a solvent (eg, ether type (eg, tetrahydrofuran, dioxane, dimethoxyethane, diethyl ether, etc.), alcohol type (eg, methanol, ethanol, etc.), benzene type (eg, Benzene, toluene, etc.), ketones (eg, acetone, methyl ethyl ketone, etc.), nitriles (eg, acetonitrile, etc.), amides (eg, N, N-dimethylformamide, etc.), water, ethyl acetate, acetic acid or their 2
- a catalyst for example, palladium-carbon, palladium black, palladium hydroxide-carbon, platinum oxide, Raney nickel, etc.
- a catalyst for example, palladium-carbon, palladium black, palladium hydroxide-carbon, platinum oxide, Raney nickel,
- the deprotection reaction of the silyl group is carried out at 0 to 40 ° C. using tetrabutylammonium fluoride in an organic solvent miscible with water (for example, tetrahydrofuran, acetonitrile, etc.).
- organic acids eg, acetic acid, trifluoroacetic acid, methanesulfonic acid, p-tosylic acid, etc.
- inorganic acids eg, hydrochloric acid, sulfuric acid, etc.
- mixtures thereof eg, hydrogen bromide / acetic acid, etc.
- the deprotection reaction using a metal is carried out in the presence of powdered zinc in an acidic solvent (for example, acetic acid, a buffer solution of pH 4.2 to 7.2 or a mixed solution thereof with an organic solvent such as tetrahydrofuran), for example. If necessary, it is carried out at 0 to 40 ° C. while applying ultrasonic waves.
- an acidic solvent for example, acetic acid, a buffer solution of pH 4.2 to 7.2 or a mixed solution thereof with an organic solvent such as tetrahydrofuran
- the deprotection reaction using a metal complex is performed by, for example, trapping reagent in an organic solvent (eg, dichloromethane, N, N-dimethylformamide, tetrahydrofuran, ethyl acetate, acetonitrile, dioxane, ethanol, etc.), water or a mixed solvent thereof.
- an organic solvent eg, dichloromethane, N, N-dimethylformamide, tetrahydrofuran, ethyl acetate, acetonitrile, dioxane, ethanol, etc.
- Electrode Eg, tributyltin hydride, triethylsilane, dimedone, morpholine, diethylamine, pyrrolidine, etc.
- organic acids eg, acetic acid, formic acid, 2-ethylhexanoic acid, etc.
- organic acid salts eg, 2-ethylhexanoic acid, etc.
- Metal complexes for example, tetrakistriphenylphosphine palladium (0), bis (dichloride), in the presence or absence of phosphine reagents (for example, triphenylphosphine) in the presence of sodium, potassium 2-ethylhexanoate, etc.
- Triphenylphosphine Radium (II), palladium (II), with tris (triphenylphosphine) rhodium (I) etc.), carried out at 0-40 ° C..
- the deprotection reaction can be performed by a method described in, for example, T. W. Greene, Protective Groups, Organic, Synthesis, Wiley, New York, 1999.
- hydroxyl protecting groups include methyl, trityl, methoxymethyl (MOM), 1-ethoxyethyl (EE), methoxyethoxymethyl (MEM), 2-tetrahydropyranyl (THP), and trimethylsilyl.
- TMS triethylsilyl
- TES triethylsilyl
- TDMS t-butyldimethylsilyl
- TDPS t-butyldiphenylsilyl
- acetyl (Ac) group pivaloyl group
- benzoyl group benzyl (Bn) group
- examples include a p-methoxybenzyl group, an allyloxycarbonyl (Alloc) group, and a 2,2,2-trichloroethoxycarbonyl (Troc) group.
- amino-protecting groups include benzyloxycarbonyl group, t-butoxycarbonyl group, allyloxycarbonyl (Alloc) group, 1-methyl-1- (4-biphenyl) ethoxycarbonyl (Bpoc) group, trifluoroacetyl group , 9-fluorenylmethoxycarbonyl group, benzyl (Bn) group, p-methoxybenzyl group, benzyloxymethyl (BOM) group, 2- (trimethylsilyl) ethoxymethyl (SEM) group and the like.
- the protecting group for the hydroxyl group and amino group is not particularly limited as long as it is a group that can be easily and selectively eliminated other than those described above.
- those described in T. W. Greene, Protective Groups in Organic Synthesis, Wiley, New York, 1999 are used.
- a compound used as a starting material for example, a compound represented by the general formula (a), (d), or (II) is known or easily produced by a known method. can do.
- reaction involving heating can be performed using a water bath, an oil bath, a sand bath, or a microwave, as will be apparent to those skilled in the art.
- a solid-phase-supported reagent supported on a polymer eg, polystyrene, polyacrylamide, polypropylene, polyethylene glycol, etc.
- a polymer eg, polystyrene, polyacrylamide, polypropylene, polyethylene glycol, etc.
- the reaction product is obtained by a conventional purification means such as distillation under normal pressure or reduced pressure, high performance liquid chromatography using silica gel or magnesium silicate, thin layer chromatography, ion exchange resin, It can be purified by scavenger resin, column chromatography, washing or recrystallization. Purification may be performed for each reaction or after completion of several reactions.
- a conventional purification means such as distillation under normal pressure or reduced pressure, high performance liquid chromatography using silica gel or magnesium silicate, thin layer chromatography, ion exchange resin, It can be purified by scavenger resin, column chromatography, washing or recrystallization. Purification may be performed for each reaction or after completion of several reactions.
- the toxicity of the compound of the present invention is sufficiently low and can be used safely as a pharmaceutical product.
- the compound of the present invention Since the compound of the present invention has Axl inhibitory activity, it can be used as a preventive and / or therapeutic agent for Axl-related diseases in mammals, particularly humans.
- examples of Axl-related diseases include cancer, kidney disease, immune system disease, and cardiovascular disease.
- examples of the cancer include acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, melanoma, breast cancer, pancreatic cancer, glioma, esophageal adenocarcinoma, Colorectal cancer, renal cell cancer, thyroid cancer, non-small cell lung cancer, prostate cancer, stomach cancer, uveal malignant melanoma, ovarian cancer, endometrial cancer, lymphoma, head and neck cancer, liver cancer, sarcoma.
- renal diseases include, for example, glomerulonephritis, chronic nephritis, IgA nephritis, secondary (secondary) nephritis, nephrotic nephritis, acute renal failure, chronic renal failure, diabetic nephropathy, gout kidney, Examples include interstitial nephritis and pyelonephritis.
- immune system diseases include psoriasis and rheumatoid arthritis.
- examples of the cardiovascular disease include atherosclerosis and thrombosis.
- the compound of the present invention since the compound of the present invention has Axl inhibitory activity, it can also be used as a tumor cell metastasis inhibitor.
- the compound of the present invention 1) complementation and / or enhancement of the prophylactic and / or therapeutic effect of the compound, It may be administered as a concomitant drug in combination with other drugs in order to 2) improve the kinetics / absorption of the compound, reduce the dose, and / or reduce the side effects of the compound.
- the concomitant drug of the compound of the present invention and another drug may be administered in the form of a combination drug containing both components in one preparation, or may be administered in separate preparations.
- simultaneous administration and administration by time difference are included.
- administration with a time difference may be such that the compound of the present invention is administered first and the other drug may be administered later, or the other drug may be administered first and the compound of the present invention may be administered later.
- Each administration method may be the same or different.
- the disease that exerts a preventive and / or therapeutic effect by the above concomitant drug is not particularly limited as long as it is a disease that complements and / or enhances the preventive and / or therapeutic effect of the compound of the present invention.
- Examples of other drugs for complementation and / or enhancement of the preventive and / or therapeutic effect of the compound of the present invention on cancer include, for example, alkylating drugs, antimetabolites, anticancer antibiotics, plant alkaloid drugs, hormone drugs Platinum compounds, anti-CD20 antibodies, anti-CD52 antibodies, G-CSF preparations, acute promyelocytic leukemia differentiation inducers, kinase inhibitors, topoisomerase inhibitors, aromatase inhibitors, and other anticancer agents.
- kidney diseases examples include, for example, steroids, immunosuppressive drugs, angiotensin II antagonists, angiotensin converting enzyme inhibitors, antiplatelet drugs And anticoagulants.
- Examples of other drugs for complementing and / or enhancing the preventive and / or therapeutic effects of the compounds of the present invention on immune system diseases include, for example, immunosuppressants, steroids, disease-modifying antirheumatic drugs, prostaglandins, and prostaglandins.
- Immunosuppressants include, for example, immunosuppressants, steroids, disease-modifying antirheumatic drugs, prostaglandins, and prostaglandins.
- Gin synthase inhibitors, phosphodiesterase inhibitors, metalloprotease inhibitors, anti-TNF- ⁇ preparations, anti-IL-1 preparations, anti-IL-6 preparations and other anti-cytokine protein preparations, cytokine inhibitors, non-steroidal anti-inflammatory drugs Can be mentioned.
- drugs for supplementing and / or enhancing the preventive and / or therapeutic effects of the compounds of the present invention on cardiovascular diseases include antiplatelet agents, angiotensin II antagonists, angiotensin converting enzyme inhibitors, HMG-CoA reductase Inhibitors and thiazolidine derivatives.
- alkylating agents include, for example, nitrogen mustard-N-oxide, cyclophosphamide, ifosfamide, melphalan, thiotepa, carbocon, busulfan, nimustine hydrochloride, dacarbazine, ranimustine, carmustine, chlorambucil, bendamustine, mecloethanamine Can be mentioned.
- antimetabolite examples include, for example, methotrexate, mercaptopurine, 6-mercaptopurine riboside, fluorouracil, tegafur, tegafur uracil, carmofur, doxyfluridine, cytarabine, enositabine, tegafur gimestat otastat potassium, gemcitabine hydrochloride, cytarabine hydrochloride, Examples include ocphosphate, procarbazine hydrochloride, and hydroxycarbamide.
- anticancer antibiotics include, for example, actinomycin D, mitomycin C, daunorubicin hydrochloride, doxorubicin hydrochloride, aclarubicin hydrochloride, neocalcinostatin, pirarubicin hydrochloride, (epirubicin hydrochloride), idarubicin hydrochloride, chromomycin A3, (hydrochloric acid hydrochloride) ) Bleomycin, pepromycin sulfate, terarubicin, dinostatin stimamarer, gemtuzumab ozogamicin and the like.
- botanical preparations include vinblastine sulfate, vincristine sulfate, vindesine sulfate, irinotecan hydrochloride, etoposide, flutamide, vinorelbine tartrate, docetaxel hydrate, paclitaxel and the like.
- hormonal agents include, for example, estramustine phosphate sodium, mepithiostane, epithiostanol, goserelin acetate, phosfestrol (diethylstilbestrol phosphate), tamoxifen citrate, toremifene citrate, phadrazole hydrochloride hydrate , Medroxyprogesterone acetate, bicalutamide, leuprorelin acetate, anastrozole, aminoglutethimide, androgen bicalutamide, fulvestrant and the like.
- platinum compounds include carboplatin, cisplatin, nedaplatin, oxaliplatin and the like.
- anti-CD20 antibodies examples include, for example, rituximab, ibritumomab, ibritumomab tiuxetan, and ocrelizumab.
- anti-CD52 antibodies examples include alemtuzumab, for example.
- G-CSF preparations include, for example, pegfilgrastim, filgrastim, lenograstim, and narutograstim.
- Examples of the acute promyelocytic leukemia differentiation inducer include tamibarotene, tretinoin, and an arsenic trioxide preparation.
- kinase inhibitors include, for example, EGFR inhibitors erlotinib hydrochloride, gefitinib, cetuximab, panitumumab, HER2 inhibitors lapatinib, trastuzumab, BCR-ABL inhibitors imatinib, dasatinib, nilotinib, multikinase inhibition
- EGFR inhibitors erlotinib hydrochloride
- gefitinib cetuximab
- panitumumab HER2 inhibitors lapatinib
- trastuzumab BCR-ABL inhibitors imatinib, dasatinib, nilotinib
- multikinase inhibition The drugs sunitinib, vandetanib, crizotinib, sorafenib are listed.
- topoisomerase inhibitors examples include, for example, topotecan, teniposide, irinotecan, and sobuzoxane.
- aromatase inhibitors include, for example, exemestane.
- anticancer agents include, for example, L-asparaginase, octreotide acetate, porfimer sodium, mitoxantrone acetic acid, acegraton, ubenimex, eribulin mesylate, cladribine, krestin, bexarotene, denileukin diftitox, temozolomide, nelarabine, fludarabine, Examples include bevacizumab, pemetrexad, pentostatin, bortezomib, lenalidomide, and folinate calcium.
- immunosuppressive drugs include azathioprine, ascomycin, everolimus, salazosulfapyridine, cyclosporine, cyclophosphamide, sirolimus, tacrolimus, bucillamine, methotrexate, leflunomide.
- steroids examples include, for example, amcinonide, hydrocortisone sodium succinate, prednisolone sodium succinate, prednisolone sodium methyl succinate, ciclesonide, difluprednate, betamethasone propionate, dexamethasone, deflazacote, triamcinolone, triamcinolone acetonide, parminolone acetonide, , Hydrocortisone, flumethasone pivalate, prednisolone butyl acetate, budesonide, plasterone sulfate, mometasone furoate, fluocinonide, fluocinolone acetonide, fludroxycortide, flunisolide, prednisolone, alclomethasone propionate, clobetasol propionate, metapionate propionate, propionate Deprodon propionate, propion Fluticasone, beclomethasone propionate, betamethasone, beta
- angiotensin II antagonist examples include losartan, candesartan, valsartan, irbesartan, olmesartan, telmisartan and the like.
- angiotensin converting enzyme inhibitors examples include alacepril, imidapril hydrochloride, quinapril hydrochloride, temocapril hydrochloride, delapril hydrochloride, benazepril hydrochloride, captopril, trandolapril, perindopril erbumine, enalapril maleate, and lisinopril.
- antiplatelet drugs examples include dipyridamole and dilazep hydrochloride hydrate.
- anticoagulants examples include warfarin and heparin.
- disease-modifying antirheumatic drugs include, for example, D-penicillamine, actarit, auranofin, salazosulfapyridine, hydroxychloroquine, bucillamine, methotrexate, leflunomide, robenzarit sodium, aurothioglucose, aurothio maleate Sodium is mentioned.
- Examples of prostaglandins include, for example, PGE1 preparations (eg: alprostadil alphadex, alprostadil etc.), PGI2 preparations (eg: beraprost sodium etc.), PG receptor agonists, Examples thereof include PG receptor antagonists.
- Examples of PG receptors include PGE receptors (EP1, EP2, EP3, EP4), PGD receptors (DP, CRTH2), PGF receptors (FP), PGI2 receptors (IP), TX receptors (TP) and the like. Can be mentioned.
- prostaglandin synthase inhibitors include, for example, salazosulfapyridine, mesalazine, olsalazine, 4-aminosalicylic acid, JTE-522, auranofin, carprofen, diphenpyramide, flunoxaprofen, flubiprofen , Indomethacin, ketoprofen, lornoxicam, loxoprofen, meloxicam, oxaprozin, parsalmid, piperoxene, piroxicam, piroxicamcinnamate, zaltoprofen, pranoprofen.
- phosphodiesterase inhibitors include, for example, rolipram, siromilast, Bay 19-8004, NIK-616, roflumilast (BY-217), cypamfilin (BRL-61063), atizolam (CP-80633), ONO-6126, SCH-355991 YM-976, V-11294A, PD-168787, D-4396, and IC-485.
- anti-TNF- ⁇ preparations include, for example, anti-TNF- ⁇ antibody, soluble TNF- ⁇ receptor, anti-TNF- ⁇ receptor antibody, soluble TNF- ⁇ binding protein, particularly inflimaxib, Etanercept.
- anti-IL-1 preparations include anti-IL-1 antibodies, soluble IL-1 receptors, anti-IL-1Ra and / or IL-1 receptor antibodies, and particularly anakinra.
- anti-IL-6 preparations include anti-IL-6 antibody, soluble IL-6 receptor, anti-IL-6 receptor antibody, and in particular, tocilizumab.
- cytokine inhibitors examples include suplatast tosylate, T-614, SR-31747, and sonatimod.
- HMG-CoA reductase inhibitors examples include atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin and the like.
- thiazolidine derivatives examples include pioglitazone, ciglitazone, rosiglitazone, and troglitazone.
- the concomitant drugs combined with the compound of the present invention include not only those found so far but also those found in the future.
- the compound of the present invention is usually administered systemically or locally in an oral or parenteral form.
- oral preparations include liquids for internal use (for example, elixirs, syrups, pharmaceutically acceptable solutions, suspensions, emulsions), solid preparations for internal use (for example, tablets (sublingual tablets, buccal cavity) Disintegrating tablets), pills, capsules (including hard capsules, soft capsules, gelatin capsules, and microcapsules), powders, granules, and troches.
- parenteral agents examples include liquids (eg, injections (subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, drops, etc.), eye drops (eg, aqueous eye drops (aqueous eye drops) Liquid, aqueous suspension ophthalmic solution, viscous ophthalmic solution, solubilized ophthalmic solution, etc.), non-aqueous ophthalmic solution (non-aqueous ophthalmic solution, non-aqueous suspension ophthalmic solution, etc.))), and external preparations (eg, ointment (eye ointment) Etc.), ear drops and the like. These preparations may be release control agents such as immediate-release preparations and sustained-release preparations. These preparations can be produced by a known method, for example, a method described in the Japanese Pharmacopoeia.
- Oral liquids for oral use are produced, for example, by dissolving, suspending or emulsifying active ingredients in diluents (eg, purified water, ethanol or a mixture thereof) generally used.
- this liquid agent may contain a wetting agent, a suspending agent, an emulsifier, a sweetening agent, a flavoring agent, a fragrance, a preservative, a buffering agent and the like.
- the solid preparation for internal use as an oral preparation includes, for example, an active ingredient as an excipient (for example, lactose, mannitol, glucose, microcrystalline cellulose, starch, etc.), a binder (for example, hydroxypropylcellulose, polyvinylpyrrolidone, aluminum metasilicate). Magnesium oxide, etc.), disintegrating agents (eg, calcium calcium glycolate), lubricants (eg, magnesium stearate), stabilizers, solubilizing agents (glutamic acid, aspartic acid, etc.), etc. According to the formulation. Moreover, you may coat
- an active ingredient as an excipient for example, lactose, mannitol, glucose, microcrystalline cellulose, starch, etc.
- a binder for example, hydroxy
- an ointment is manufactured by kneading or melting an active ingredient in a base.
- the ointment base is selected from known or commonly used ones.
- higher fatty acids or higher fatty acid esters for example, adipic acid, myristic acid, palmitic acid, stearic acid, oleic acid, adipic acid ester, myristic acid ester, palmitic acid ester, stearic acid ester, oleic acid ester, etc.
- waxes E.g., beeswax, whale wax, ceresin, etc.
- surfactants e.g., polyoxyethylene alkyl ether phosphates, etc.
- higher alcohols e.g., cetanol, stearyl alcohol, cetostearyl alcohol, etc.
- silicone oils e.g., Dimethylpolysiloxane, etc.
- hydrocarbons eg, hydrophilic petrolatum, white petrolatum, purified lanolin, liquid paraffin, etc.
- glycols eg, ethylene glycol, diethylene glycol, propylene glycol, polyethylene
- glycols e
- the parenteral injection includes solutions, suspensions, emulsions and solid injections used by dissolving or suspending in a solvent at the time of use.
- An injection is used, for example, by dissolving, suspending or emulsifying an active ingredient in a solvent.
- the solvent for example, distilled water for injection, physiological saline, vegetable oil, propylene glycol, polyethylene glycol, alcohols such as ethanol, and combinations thereof are used.
- this injection contains a stabilizer, a solubilizing agent (for example, glutamic acid, aspartic acid, polysorbate 80 (registered trademark), etc.), a suspending agent, an emulsifying agent, a soothing agent, a buffering agent, a preservative and the like.
- a sterile solid preparation for example, a lyophilized product, can be produced and used by dissolving it in sterilized or sterile distilled water for injection or other solvent before use.
- the compound of the present invention or the concomitant agent of the compound of the present invention and another drug for the above purpose is usually administered systemically or locally in an oral or parenteral form.
- the dose varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc., but is usually orally administered once to several times a day in the range of 1 ng to 1000 mg per adult per dose. Or administered parenterally once or several times a day in the range of 0.1 ng to 100 mg per adult or continuously intravenously in the range of 1 to 24 hours per day.
- an amount smaller than the above dosage may be sufficient, or administration may be necessary beyond the range.
- NH silica indicates that CHROMATOREX NH TLC PLATE (catalog number; 3800003) manufactured by Fuji Silysia was used, and the description of DNH silica used CHROMATOREX NH TLC PLATE (catalog number; 3004003) manufactured by Fuji Silysia. Represents the effect.
- LC-MS / ELSD is as follows: ⁇ Column: Waters ACQUITY C 18 (particle size: 1.7 x 10 -6 m; column length: 30 x 2.1 mm ID); flow rate: 1.0 mL / min; column temperature: 40 ° C; mobile phase (A): 0. 1% formic acid aqueous solution; mobile phase (B): 0.1% formic acid-acetonitrile solution; gradient (describe ratio of mobile phase (A): mobile phase (B)): [0 min] 95: 5; [0. [1 minute] 95: 5; [1.2 minutes] 5:95; [1.4 minutes] 5:95; [1.41 minutes] 95: 5; [1.5 minutes] 95: 5; UV (PDA), ELSD, MS ⁇ I went there.
- the parentheses shown in the NMR part indicate the solvent used for the measurement.
- the compound name used in this specification is generally a computer program for naming according to the IUPAC rules, Advanced Chemistry Development ACD / Name (registered trademark), or according to the IUPAC nomenclature. It is named.
- Example 1 4-[(6-Chloro-3-pyridinyl) oxy] -6,7-dimethoxyquinoline 4-Chloro-6,7-dimethoxyquinoline (39 g) in a 2 L four-necked flask under a nitrogen stream (CAS registration number: 35654-56-9) in chlorobenzene (400 mL), 6-chloropyridin-3-ol (25 g), 4-dimethylaminopyridine (DMAP) (64 g) were added, and bath temperature (140 ° C.) For 42 hours. After allowing to cool to room temperature, water (700 mL) and ethyl acetate (1 L) were added to separate the layers.
- DMAP 4-dimethylaminopyridine
- Example 2 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinamine
- THF tetrahydrofuran
- Example 3 N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2-oxo-1-phenyl-1,2-dihydro-3-pyridinecarboxamide 2 at room temperature -Oxo-1-phenyl-1,2-dihydropyridine-3-carboxylic acid (CAS registration number: 868171-81-7) (1.9 g), O- (7-aza-1-benzotriazolyl) -N, N, N ′, N′-tetramethyluronium hexafluorophosphate (HATU) (4.1 g) was dissolved in N, N-dimethylformamide (DMF) (50 mL) and diisopropylethylamine (DIPEA) (2.3 g) was carried out.
- DMF N-dimethylformamide
- DIPEA diisopropylethylamine
- Example 2 The compound prepared in Example 2 (2.7 g) was added and stirred for 21 hours. Water was added to the reaction solution to precipitate a solid. The solid obtained by filtration was washed with ethanol and dried under reduced pressure to obtain the title compound (3.6 g) having the following physical property values.
- Example 3 (1) to 3 (2) Using the compound prepared in Example 2 and the corresponding carboxylic acid derivative instead of 2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylic acid, the same procedure as in Example 3 was performed. As a result, the following Example compounds were obtained.
- Example 3 N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -5-oxo-2,3-dihydro-1H, 5H-pyrido [3 2,1-ij] quinoline-6-carboxamide
- Example 4 Methyl 5-acetyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate 5-acetyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (CAS registration number: 88302-06-1) (450 mg) was dissolved in methanol (20 mL), oxalyl chloride (0.43 mL) was added dropwise at 0 ° C., and the mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure, saturated sodium hydrogen carbonate was added to the resulting residue, and the mixture was extracted with dichloromethane.
- Example 5 5-acetyl-6-methyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylic acid
- dichloromethane 10 mL
- phenylboric acid 580 mg
- diacetoxy copper (II) 870 mg
- pyridine 5.0 mL
- 4 ⁇ molecular sieves 1.0 g
- Example 6 5-acetyl-N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -6-methyl-2-oxo-1-phenyl-1,2-dihydro -3-pyridinecarboxamide
- the title compound (12 mg) having the following physical property values was obtained by subjecting the compound (20 mg) prepared in Example 5 and the compound (20 mg) prepared in Example 2 to the same intended operation as in Example 3. Obtained.
- Example 7 4-[(6-Chloro-3-pyridinyl) oxy] -6,7-dimethoxyquinazoline 4-chloro-6,7 dimethoxyquinazoline (CAS registration number: 13790-39-1) under argon atmosphere 8.0 g), DMAP (4.4 g) was added to a DMSO suspension (20 mL) of 6-chloropyridin-3-ol (4.6 g), and the mixture was heated and stirred at a bath temperature (80 ° C.) for 2 hours. After allowing to cool to room temperature, the reaction mixture was diluted with ethyl acetate and washed with water and saturated aqueous sodium hydrogen carbonate solution.
- Example 8 5-[(6,7-dimethoxy-4-quinazolinyl) oxy] -2-pyridinamine hydrochloride 1.0 mol of the compound prepared in Example 7 (1.0 g) in THF (15 mL) under an argon atmosphere / L LHDMS (4.7 mL), tris (dibenzylideneacetone) dipalladium (0) chloroform complex (140 mg), 2-dicyclohexylphosphino-2 ′, 6′-dimethoxybiphenyl (170 mg) were added, and the bath temperature (70 ) For 4 hours. The reaction mixture was allowed to cool to room temperature, poured into ice water, and extracted with ethyl acetate.
- Example 9 5-acetyl-N- ⁇ 5-[(6,7-dimethoxy-4-quinazolinyl) oxy] -2-pyridinyl ⁇ -6-methyl-2-oxo-1-phenyl-1,2-dihydro -3-pyridinecarboxamide
- the title compound (14 mg) having the following physical property values was obtained by subjecting the compound (25 mg) produced in Example 5 and the compound (28 mg) produced in Example 8 to the same intended operation as in Example 3. Obtained.
- Example 10 2,2-Dimethylpropyl 5-bromo-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylate To dichloromethane (60 mL) was added 2,2-dimethylpropyl 5-bromo-2- Using hydroxypyridine-3-carboxylate (2.0 g), phenylboric acid (1.7 g), diacetoxy copper (II) (5.2 g), and pyridine (15 mL) were added, and the mixture was stirred at room temperature for 16 hours under an oxygen atmosphere. did. The reaction solution was filtered through Celite to remove insoluble solids, diluted with dichloromethane, and the organic layer was washed with water and 1 mol / L hydrochloric acid. The obtained organic layer was dried over sodium sulfate and filtered, and then the solvent was distilled off by concentration under reduced pressure to obtain the title compound (1.5 g) having the following physical property values. MS (M + H): 364.
- Example 11 2,2-Dimethylpropyl 5- (3-hydroxy-3-methylbut-1-in-1-yl) -2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylate 10 (100 mg) was dissolved in acetonitrile (10 mL), 2-methyl-3-butyn-2-ol (51 mg), tris (tert-butyl) phosphine (1.0 mL), tetrakis (triphenylphosphine) Palladium (0) (32 mg), copper (I) iodide (3.0 mg) and triethylamine (0.2 mL) were added, and the mixture was stirred at 70 ° C. for 16 hr.
- Example 12 5- (3-Hydroxy-3-methylbut-1-in-1-yl) -2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylic acid
- Compound prepared in Example 11 50 mg was dissolved in a mixed solvent of methanol / water (4: 1, 3.5 mL), lithium hydroxide monohydrate (4.0 mg) was added, and the mixture was stirred at room temperature for 16 hours.
- 1N Hydrochloric acid was added to the reaction mixture, and the organic layer was extracted with dichloromethane, dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give the title compound (32 mg) having the following physical data.
- Example 13 N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -5- (3-hydroxy-3-methyl-1-butyn-1-yl) -2 -Oxo-1-phenyl-1,2-dihydro-3-pyridinecarboxamide trifluoroacetate Using the compound prepared in Example 12 (25 mg) and the compound prepared in Example 2 (25 mg), The title compound (10 mg) having the following physical property values was obtained by subjecting it to the same intended operation.
- Examples 13 (1) to 13 (2) The following example compound was obtained by subjecting the corresponding quinoline derivative instead of the compound produced in Example 2 and the compound produced in Example 12 to the same operation as in Example 3.
- Example 13 5- (3-hydroxy-3-methyl-1-butyn-1-yl) -N- ⁇ 5-[(7-methoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ - 2-Oxo-1-phenyl-1,2-dihydro-3-pyridinecarboxamide (LC-MS / ELSD): (Retention time: 0.86 minutes); 1 H-NMR (CDCl 3 ): ⁇ 1.60, 2.00, 3.97, 6.43, 7.23, 7.38-7.44, 7.51-7.59, 7.81, 8.20-8.26, 8.46, 8.61, 8.71, 12.24.
- Example 14 3-Bromo-1-phenyl-5- (trifluoromethyl) -2 (1H) -pyridinone 3-Bromo-5- (trifluoromethyl) pyridin-2 (1H) -one (1.0 g)
- the title compound (1.1 g) having the following physical data was obtained by subjecting it to the same operation as in Example 10.
- Example 15 Methyl 2-oxo-1-phenyl-5- (trifluoromethyl) -1,2-dihydro-3-pyridinecarboxylate
- DMF 8.0 mL
- methanol 8.0 mL
- a mixed solvent 8.0 mL
- Palladium (II) acetate 36 mg
- 1,1′-bis (diphenylphosphino) ferrocene 88 mg
- triethylamine (0.33 mL) were added, and the mixture was stirred at 90 ° C. for 16 hours under a carbon monoxide atmosphere (100 psi). .
- Example 16 2-Oxo-1-phenyl-5- (trifluoromethyl) -1,2-dihydro-3-pyridinecarboxylic acid
- the compound prepared in Example 15 (100 mg) was dissolved in THF (2 mL).
- Sodium trimethylsilanolate (38 mg) was added and stirred at room temperature for 3 hours.
- the reaction solution was filtered, and the resulting precipitate was washed with THF to obtain the title compound (45 mg) having the following physical property values.
- Example 17 N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2-oxo-1-phenyl-5- (trifluoromethyl) -1,2-dihydro -3-Pyridinecarboxamide
- Examples 17 (1) to 17 (2) The following example compound was obtained by subjecting the corresponding quinoline derivative instead of the compound produced in Example 2 and the compound produced in Example 16 to the same operation as in Example 3.
- Example 17 N- ⁇ 5-[(7-methoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2-oxo-1-phenyl-5- (trifluoromethyl) -1,2- Dihydro-3-pyridinecarboxamide (LC-MS / ELSD): (Retention time: 0.93 minutes); 1 H-NMR (CD 3 OD): ⁇ 3.97, 6.44, 7.19-7.25, 7.38-7.50, 7.53-7.67, 8.02-8.06, 8.22, 8.26, 8.47, 8.61, 8.90, 12.08.
- Example 17 (2): N- ⁇ 5-[(6-methoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2-oxo-1-phenyl-5- (trifluoromethyl) -1,2- Dihydro-3-pyridinecarboxamide (LC-MS / ELSD): (Retention time: 0.88 minutes); 1 H-NMR (CDCl 3 ): ⁇ 3.96, 6.54, 7.39-7.44, 7.56-7.60, 8.00, 8.02-8.04, 8.27, 8.47, 8.56, 8.89, 12.07.
- Example 18 Methyl 5- (1-ethoxyethenyl) -2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylate Methyl 5-bromo-2-oxo-1-phenyl-1,2- Dihydropyridine-3-carboxylate (CAS Registry Number: 381248-02-8) (100 mg) and tributyl (1-ethoxyvinyl) tin (0.11 mL) were dissolved in 1,4-dioxane (2 mL) and palladium (0 ) Tetrakis (triphenylphosphine) (8 mg) was added and stirred in a sealed tube at 100 ° C. for 16 hours.
- Example 19 Methyl 5-acetyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylate
- THF 5 mL
- 2 mol / L hydrochloric acid 2 mL
- the reaction solution was concentrated under reduced pressure, water was added to the resulting residue, and the mixture was extracted with ethyl acetate.
- the obtained organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure to give the title compound (80 mg) having the following physical data.
- Example 20 5-acetyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylic acid
- the compound prepared in Example 19 (80 mg) was mixed with THF / water (4: 1, 5 mL). And lithium hydroxide monohydrate (62 mg) was added and allowed to stir at room temperature for 16 hours.
- 1N Hydrochloric acid was added to the reaction mixture, and the organic layer was extracted with dichloromethane, dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give the title compound (50 mg) having the following physical data.
- 1 H-NMR (CDCl 3 ) ⁇ 2.59, 7.39-7.42, 7.58-7.62, 8.47, 9.07.
- Example 21 5-acetyl-N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2-oxo-1-phenyl-1,2-dihydro-3-pyridine Carboxamide
- the title compound (17.5 mg) having the following physical properties was obtained by subjecting the compound (50 mg) prepared in Example 20 and the compound (50 mg) prepared in Example 2 to the same operation as in Example 3. ) (LC-MS / ELSD): (Retention time: 0.73 minutes); 1 H-NMR (CDCl 3 ): ⁇ 2.60, 4.05, 6.47, 7.53-7.60, 8.27, 8.46, 8.47, 8.49, 8.52, 9.20, 12.00.
- Example 22 Ethyl 6- (tert-butoxycarbonyl) -2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-1,6-naphthyridine-3-carboxylate at room temperature , Tert-butyl 2,4-dioxopiperidine-1-carboxylate (CAS registration number: 845267-78-9) (3.0 g) was dissolved in DMF, and tert-butoxypotassium (13 g), ethyl (2E)- 2-Cyano-3-ethoxyprop-2-enoate (CAS registration number: 94-05-3) (2.4 g) was added and stirred for 21 hours.
- Tert-butoxypotassium 13 g
- ethyl (2E)- 2-Cyano-3-ethoxyprop-2-enoate CAS registration number: 94-05-3
- Example 23 6- (tert-Butoxycarbonyl) -2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-1,6-naphthyridine-3-carboxylic acid
- the compound prepared in Example 22 66 mg
- aniline 36 mg
- the solid precipitated from the reaction solution was collected by filtration with a Kiriyama funnel, washed with ethanol, and the obtained residue was dried under reduced pressure to obtain the title compound (84 mg) having the following physical property values.
- Example 24 2-Methyl-2-propanyl 3-( ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ carbamoyl) -2,5-dioxo-1-phenyl-1 , 5,7,8-Tetrahydro-1,6-naphthyridine-6 (2H) -carboxylate
- the title compound (46 mg) having the following physical data was obtained by subjecting it to the same procedure as in 3.
- Example 25 N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2,5-dioxo-1-phenyl-1,2,5,6,7,8 -Hexahydro-1,6-naphthyridine-3-carboxamide
- the compound prepared in Example 24 (40 mg) was dissolved in dichloromethane (3 mL), trifluoroacetic acid (1 mL) was added, and the mixture was stirred at room temperature for 20 minutes.
- the reaction solution was neutralized with a saturated aqueous sodium hydrogen carbonate solution, and extracted with dichloromethane.
- Example 26 Ethyl 3-anilino-3-oxopropanoate After adding aniline (3.1 g), DMAP (0.61 g), triethylamine (5.1 mL), dichloromethane (25 mL) to a 300 mL 3-diameter eggplant flask, ice In a bath, a solution of ethyl malonyl chloride (5.0 g) in dichloromethane (25 mL) was added dropwise over 20 minutes. After stirring for 30 minutes, water was added and dichloromethane was distilled off under reduced pressure.
- Example 27 Ethyl 2-oxo-1-phenyl-1,2-dihydro-1,7-naphthyridine-3-carboxylate
- the compound prepared in Example 26 (560 mg) was dissolved in toluene (10 mL), and 3- Bromopyridine-4-carbaldehyde (500 mg), tris (dibenzylideneacetone) dipalladium (0) (120 mg), 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (160 mg) and cesium carbonate ( 1800 mg) was added and stirred at 150 ° C. for 1 hour. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate.
- Example 28 N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2-oxo-1-phenyl-1,2-dihydro-1,7-naphthyridine-3 -Carboxamide
- Example 3 N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2-oxo-1-phenyl-1,2-dihydro-1,7-naphthyridine-3 -Carboxamide
- Example 29 7-benzyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2 (1H) -one 1,7-naphthyridin-2 (1H) -one (CAS Registry Number: 54920-82 -0) (900 mg) was added ethanol (20 mL) and benzyl bromide (0.8 mL), and the mixture was heated and stirred at 80 ° C. for 18 hours. After cooling to 0 ° C., sodium borohydride (1100 mg) was added and stirred for 10 minutes at 0 ° C., then hydrochloric acid was added and stirred for 90 minutes at room temperature.
- Example 30 5,6,7,8-Tetrahydro-1,7-naphthyridin-2 (1H) -one trifluoroacetate salt
- the compound prepared in Example 29 (800 mg) was dissolved in methanol (10 mL), Fluoroacetic acid (0.27 mL) and palladium carbon (160 mg) were added, and the mixture was stirred at room temperature for 5 hours under a hydrogen gas atmosphere.
- the reaction solution was filtered through celite, and the solvent was evaporated under reduced pressure to give the title compound (800 mg) having the following physical data.
- Example 31 tert-Butyl 2-oxo-2,5,6,8-tetrahydro-1,7-naphthyridine-7 (1H) -carboxylate
- THF 10 mL
- triethylamine 1.3 mL
- di-tert-butyl dicarbonate 0.85 mL
- Water was added to the reaction solution, and the mixture was extracted with ethyl acetate.
- the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure.
- Example 32 tert-Butyl 3-Bromo-2-oxo-2,5,6,8-tetrahydro-1,7-naphthyridine-7 (1H) -carboxylate
- the compound prepared in Example 31 (490 mg) was converted to DMF. (5 mL), N-bromosuccinimide (360 mg) was added, and the mixture was stirred at room temperature for 2 hours.
- the reaction solution was diluted with ethyl acetate, water was added, and the organic layer was extracted. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to give the title compound (560 mg) having the following physical data.
- Example 33 7-tert-butyl 3-methyl 2-oxo-1-phenyl-2,5,6,8-tetrahydro-1,7-naphthyridine-3,7 (1H) -dicarboxylate in Example 32
- the title compound (96 mg) having the following physical data was obtained by subjecting the produced compound (1400 mg) to the same intended operation as in Example 10 ⁇ Example 14.
- (LC-MS / ELSD): (Retention time: 1.01 minutes); TLC: Rf 0.54 (hexane: ethyl acetate 1: 1).
- Example 34 tert-butyl 3-( ⁇ 5-[(6,7-dimethoxyquinolin-4-yl) oxy] pyridin-2-yl ⁇ carbamoyl) -2-oxo-1-phenyl-2,5,6 , 8-Tetrahydro-1,7-naphthyridine-7 (1H) -carboxylate
- the title compound (29 mg) having the following physical data was obtained by subjecting the produced compound (17 mg) to the same procedure as in Example 3.
- TLC: Rf 0.83 (ethyl acetate: methanol 10: 1, NH silica); (LC-MS / ELSD): (Retention time: 0.95 minutes).
- Example 35 N- ⁇ 5-[(6,7-dimethoxyquinolin-4-yl) oxy] pyridin-2-yl ⁇ -2-oxo-1-phenyl-1,2,5,6,7,8 -Hexahydro-1,7-naphthyridine-3-carboxamide trifluoroacetate salt
- the compound prepared in Example 34 25 mg was dissolved in dichloromethane (1 mL), trifluoroacetic acid (0.03 mL) was added, and room temperature was added. For 3 hours. The reaction solution was concentrated under reduced pressure to obtain the title compound (28 mg) having the following physical property values.
- Example 36 7- (2-Butinoyl) -N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2-oxo-1-phenyl-1,2,5 , 6,7,8-Hexahydro-1,7-naphthyridine-3-carboxamide
- the title compound (8.0 mg) having the following physical data is obtained by subjecting the compound (25 mg) and 2-butyric acid (3.6 mg) produced in Example 35 to the same intended operations as in Example 3. It was.
- Example 37 3-Chlorocyclohex-2-en-1-one A solution of cyclohexane-1,3-dione (CAS registration number: 504-02-9) (5.0 g) in dichloromethane (230 mL) in an ice bath. , Methanesulfonyl chloride (3.5 mL) and potassium carbonate (19 g) were added and stirred for 4 hours. The reaction mixture was washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure until the solution reached about 150 mL.
- Example 38 2-Cyano-2- (3-oxocyclohex-1-en-1-yl) acetamide
- sodium hydride 550 mg
- diethylene glycol dimethyl ether 5.0 mL
- 2-cyanoacetamide 1.2 g
- diethylene glycol dimethyl ether 7.0 mL
- a solution of the compound prepared in Example 37 (1.2 g) in diethylene glycol dimethyl ether (13 mL) was added and the reaction mixture was stirred for 8 hours.
- the reaction mixture was poured into aqueous hydrochloric acid and extracted with ethyl acetate.
- Example 39 3,8-Dioxo-2,3,5,6,7,8-hexahydroisoquinoline-4-carbonitrile N, N-dimethylformamide (16 mL) of the compound prepared in Example 38 (830 mg) N, N-dimethylformamide dimethyl acetal (740 ⁇ L) was added to the solution and stirred for 4 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was washed with ethyl acetate and collected by filtration to give the title compound (350 mg) having the following physical data. TLC: Rf 0.52 (ethyl acetate); 1 H-NMR (CD 3 OD): ⁇ 2.10-2.20, 2.62, 3.08, 8.35.
- Example 40 3,8-Dioxo-2-phenyl-2,3,5,6,7,8-hexahydroisoquinoline-4-carbonitrile
- Dichloromethane solution (12 mL) of the compound prepared in Example 39 300 mg
- phenylboronic acid (780 mg), 4 ⁇ molecular sieve (300 mg), copper (II) acetate (580 mg) and pyridine (520 ⁇ L) were added, and the mixture was stirred overnight.
- Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane. The obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Example 41 3,8-Dioxo-2-phenyl-2,3,5,6,7,8-hexahydroisoquinoline-4-carboxylic acid To the compound prepared in Example 40 (20 mg), water (0.1 mL) ) And concentrated sulfuric acid (0.1 mL) were added. The reaction mixture was stirred at 100 ° C. overnight. The reaction mixture was poured into aqueous sodium hydroxide and washed with ethyl acetate. To the aqueous layer was added aqueous hydrochloric acid solution, and the mixture was extracted with ethyl acetate.
- Example 42 N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -3,8-dioxo-2-phenyl-2,3,5,6,7,8 -Hexahydro-4-isoquinolinecarboxamide
- the title compound (4.0) having the following physical property values was obtained by subjecting the compound (6.3 mg) prepared in Example 41 and the compound (6.6 mg) prepared in Example 2 to the same target operations as in Example 3. mg).
- Example 42 N- ⁇ 4-[(6,7-dimethoxy-4-quinolinyl) oxy] -3-fluorophenyl ⁇ -3,8-dioxo-2-phenyl-2,3,5,6 , 7,8-Hexahydro-4-isoquinolinecarboxamide
- Example 43 Methyl 2-oxo-1-[(1S) -1-phenylethyl] -1,2-dihydropyridine-3-carboxylate
- Methyl 2-oxopyran-3-carboxylate (CAS Registry Number: 25991-27- 9) (8.4 g) and (1S) -1-phenylethylamine (7.9 g) were dissolved in DMF (100 mL) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (14 g) and N, N-dimethylpyridin-4-amine (0.67 g) was added and stirred at room temperature for 16 hours.
- Example 45 5-iodo-2-oxo-1-[(1S) -1-phenylethyl] -1,2-dihydropyridine-3-carboxylic acid
- the compound prepared in Example 44 (3.0 g) was dissolved in dichloromethane (12 mL). ), Trifluoroacetic acid (12 mL) and N-iodosuccinimide (3.3 g) were added, and the mixture was stirred at room temperature for 12 hours. Water was added to the reaction solution, and the mixture was extracted with dichloromethane. The obtained organic layer was washed with sodium thiosulfate, dried over sodium sulfate, filtered, and concentrated under reduced pressure.
- Example 46 N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -5-iodo-2-oxo-1-[(1S) -1-phenylethyl]- 1,2-Dihydro-3-pyridinecarboxamide
- Example 47 N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2-oxo-1-[(1S) -1-phenylethyl] -1,2- Dihydro-3-pyridinecarboxamide
- the compound prepared in Example 46 (100 mg) was dissolved in ethanol (4 mL), 10% palladium-carbon (20 mg) was added, and the mixture was stirred at room temperature for 3 hours in a hydrogen atmosphere. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure.
- Example 48 Ethyl 3-anilino-3-oxopropanoate Add aniline (3.1 g), 4-dimethylaminopyridine (0.61 g), triethylamine (5.1 mL) and dichloromethane (25 mL) to a 300 mL 3-diameter flask. Then, a solution of ethyl malonyl chloride (5.0 g) in dichloromethane (25 mL) was added dropwise over 20 minutes in an ice bath. After stirring for 30 minutes, water was added and dichloromethane was distilled off under reduced pressure.
- Example 49 6-Methyl-2-oxo-1-phenyl-1,2-dihydro-3-pyridinecarboxylic acid
- the compound prepared in Example 48 (5.8 g), (E) -4- Methoxy-3-buten-2-one (3.1 g), 20% sodium ethoxide solution in ethanol (11.4 g), and methanol (30 mL) were added. After refluxing for 16 hours, the mixture was allowed to cool to room temperature, and the solvent was distilled off under reduced pressure. Subsequently, 2N aqueous sodium hydroxide solution (30 mL) and methanol (30 mL) were added to the resulting residue, and the mixture was stirred at room temperature for 23 hours.
- Example 50 Methyl 6-methyl-2-oxo-1-phenyl-1,2-dihydro-3-pyridinecarboxylate
- the compound prepared in Example 49 (2.9 g), methanol (29 mL), in a 200 mL eggplant flask, Ethyl acetate (29 mL) and trimethylsilyldiazomethane were added.
- the title compound (2.9 g) having the following physical data was obtained by evaporating the solvent under reduced pressure.
- TLC Rf 0.34 (ethyl acetate); 1 H-NMR (CDCl 3 ): ⁇ 2.04, 3.88, 6.22, 7.18, 7.50, 8.20.
- Example 51 Methyl 5-bromo-6- (bromomethyl) -2-oxo-1-phenyl-1,2-dihydro-3-pyridinecarboxylate
- N-bromosuccinimide 3.1 g
- benzoyl peroxide 40 mg
- carbon tetrachloride 36 mL
- Example 52 Methyl 6-[(bis ⁇ [(2-methyl-2-propanyl) oxy] carbonyl ⁇ amino) methyl] -5-bromo-2-oxo-1-phenyl-1,2-dihydro-3- Pyridinecarboxylate Compound prepared in Example 51 (2.5 g), di-tert-butylimidodicarbonate (Boc 2 NH) (1.6 g), potassium carbonate (1.7 g), DMF (30 mL) in a 100 mL eggplant flask Was added.
- Example 53 6-[(bis ⁇ [(2-methyl-2-propanyl) oxy] carbonyl ⁇ amino) methyl] -5-bromo-2-oxo-1-phenyl-1,2-dihydro-3-pyridine
- 2N aqueous sodium hydroxide solution (14 mL) 2N aqueous sodium hydroxide solution (14 mL)
- methanol 14 mL
- 1N Hydrochloric acid was added to the reaction mixture, and the precipitated powder was collected by filtration and dried to give the title compound (2.3 g) having the following physical data.
- TLC Rf 0.57 (ethyl acetate);
- Example 54 Bis (2-methyl-2-propanyl) ⁇ [3-bromo-5-( ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ carbamoyl) -6- Oxo-1-phenyl-1,6-dihydro-2-pyridinyl] methyl ⁇ imide dicarbonate
- Example 3 using the compound prepared in Example 53 (530 mg) and the compound prepared in Example 2 (300 mg) The title compound (770 mg) having the following physical property values was obtained by subjecting the same procedure to that described above.
- Example 55 6- (aminomethyl) -N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2-oxo-1-phenyl-1,2-dihydro- 3-Pyridinecarboxamide
- the compound produced in Example 54 (100 mg) was dissolved in ethanol (2 mL), 10% palladium-carbon (100 mg) and 1 mol / L hydrochloric acid (0.6 mL) were added, and the mixture was heated at 60 ° C. under a hydrogen atmosphere. For 3 hours. After confirming disappearance of the raw materials, the reaction solution was filtered through Celite, and the filtrate was concentrated under reduced pressure.
- Example 56 6-[(2-butinoylamino) methyl] -N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2-oxo-1-phenyl- 1,2-Dihydro-3-pyridinecarboxamide
- the title compound (38 mg) having the following physical data was obtained by subjecting the compound (45 mg) produced in Example 55 to the same intended operation as in Example 36. It was.
- Example 57 N- ⁇ 5-[(6,7-dimethoxyquinolin-4-yl) oxy] pyridin-2-yl ⁇ -5-iodo-2-oxo-1-phenyl-1,2-dihydropyridine-3 —Carboxamide
- the title compound (1.3 g) having the following physical data was obtained by subjecting the compound (1.4 g) produced in Example 3 to the same target operation as in Example 45.
- TLC: Rf 0.50 (hexane: ethyl acetate 4: 1);
- Example 58 2-methyl-2-propanyl ⁇ 3- [5-( ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ carbamoyl) -6-oxo-1-phenyl -1,6-Dihydro-3-pyridinyl] -2-propin-1-yl ⁇ carbamate
- N, N-dimethylformamide (5.0 mL) N-Boc-propargyl Amine (220 mg), copper (I) iodide (13 mg), tetrakis (triphenylphosphine) palladium (0) (81 mg), N, N-diisopropylethylamine (360 ⁇ L) were added, and the mixture was stirred overnight under an argon atmosphere.
- Example 59 2-methyl-2-propanyl ⁇ 3- [5-( ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ carbamoyl) -6-oxo-1-phenyl -1,6-Dihydro-3-pyridinyl] propyl ⁇ carbamate
- the title compound having the following physical property values ( 200 mg) was obtained.
- Example 60 5- (3-aminopropyl) -N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2-oxo-1-phenyl-1,2- Dihydro-3-pyridinecarboxamide
- TLC Rf 0.11 (ethyl acetate, NH silica); 1 H-NMR (CDCl 3 ): ⁇ 1.75-1.88, 2.67, 2.77-2.85, 4.05, 6.46, 7.38-7.59, 8.25, 8.46, 8.50, 8.64, 12.57.
- Example 61 5- [3- (2-Butinoylamino) propyl] -N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2-oxo-1- Phenyl-1,2-dihydro-3-pyridinecarboxamide
- the title compound (44 mg) having the following physical data was obtained by subjecting the compound (89 mg) prepared in Example 60 to the same intended operation as in Example 36. Got.
- Example 62 Ethyl 2,5-dioxo-5,6,7,8-tetrahydro-2H-chromene-3-carboxylate 1,3-cyclohexanedione (CAS Registry Number: 504-02-9) at room temperature (13 g )
- N N-dimethylformamide
- tert-butoxypotassium 13 g
- ethyl (E) -2-cyano-3-ethoxy-2-propenoate (CAS registration number: 94-05) -3) (20 g) was added and stirred for 21 hours.
- the reaction solution was diluted with ethyl acetate, and 2N aqueous hydrochloric acid solution was added and stirred.
- Example 63 2,5-Dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxylic acid
- the compound prepared in Example 62 (10.00 g) at room temperature with ethanol (200 mL) ), Aniline (3.94 g) was added, and the mixture was stirred for 6 hours.
- the solid precipitated from the reaction solution was filtered with a Kiriyama funnel, washed with ethanol, and the resulting residue was dried under reduced pressure at 60 ° C.
- the title compound (4.01 g) having the following physical data was obtained.
- Example 64 (5E) -5- (hydroxyimino) -4-methyl-2-oxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxylic acid
- Example 63 The prepared compound (140 mg) and hydroxylamine hydrochloride (210 mg) in pyridine (1.0 mL) were heated to reflux for 1 hour. After cooling to room temperature, the reaction solution was diluted with ethyl acetate and washed with 1 mol / L hydrochloric acid. The obtained organic layer was concentrated to obtain the title compound (150 mg) having the following physical property values.
- Example 65 N- ⁇ (5E) -5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -5- (hydroxyimino) -2-oxo-1-phenyl-1, 2,5,6,7,8-Hexahydro-3-quinolinecarboxamide Using the compound (65 mg) prepared in Example 64 and the compound (50 mg) prepared in Example 2, the same purpose as in Example 3 was used. By subjecting to operation, the title compound (59 mg) having the following physical property values was obtained.
- Example 66 N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2,5-dioxo-1-phenyl-2,5,6,7,8,9 -Hexahydro-1H-pyrido [3,2-c] azepine-3-carboxamide
- Triethylamine 9 ⁇ L
- dimethylaminopyridine 0. mg
- paratoluenesulfonyl chloride 13 mg
- the reaction solution was diluted with dichloromethane, washed with water, the organic layer was dried over anhydrous sodium sulfate, and the solvent was distilled off.
- a 50% trifluoroacetic acid-dichloromethane solution (2 mL) was added to the resulting residue, and the mixture was heated with stirring in an oil bath at 70 ° C. for 16 hours.
- the reaction mixture was concentrated, and the resulting residue was purified by silica gel column chromatography (Chromatolex DNH, ethyl acetate: methanol 1: 0 ⁇ 20: 1) to obtain the title compound (12 mg) having the following physical property values.
- Example 67 Diethyl (4-bromo-2-nitrobenzylidene) propanedioate 4-Bromo-2-nitrobenzaldehyde (CAS registration number: 5551-12-2) (2.0 mg) was dissolved in acetic anhydride (40 mL). , Diethyl malonate (1.4 g) and potassium carbonate (1.8 g) were added, and the mixture was stirred at 80 ° C. for 4 hr. The reaction solution was allowed to cool to room temperature, poured into ice-cold water, and extracted with dichloromethane. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product (3.2 g) containing the title compound, which was used in the next reaction without purification.
- Example 68 Ethyl 7-bromo-2-oxo-1,2-dihydroquinoline-3-carboxylate
- the crude product prepared in Example 67 (2.8 g) was dissolved in acetic acid (24 mL) and iron powder (4.2 g) was added and stirred at 80 ° C. for 4 hours.
- the reaction solution was filtered through Celite, and the filtrate was neutralized with a saturated aqueous sodium hydrogen carbonate solution, and extracted with dichloromethane.
- the organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure.
- the obtained residue was washed with tert-butyl methyl ether to give the title compound (1.2 g) having the following physical data.
- 1 H-NMR (CDCl 3 ) ⁇ 1.45, 4.45, 7.34-7.41, 7.48-7.56, 8.50, 10.94.
- Example 69 Ethyl 7-bromo-2-oxo-1-phenyl-1,2-dihydroquinoline-3-carboxylate
- phenylboric acid 1.0 g
- dichloromethane 200 mL
- Diacetoxycopper (II) 1.5 g
- pyridine 4.0 mL
- 4 mol molecular sieves 4 mol molecular sieves were added, and the mixture was stirred at room temperature for 64 hours under an oxygen atmosphere.
- the reaction solution was filtered through Celite to remove insoluble solids, diluted with dichloromethane (200 mL), and the organic layer was washed with water.
- Example 70 Ethyl 7-[(tert-butoxycarbonyl) amino] -2-oxo-1-phenyl-1,2-dihydroquinoline-3-carboxylate prepared in Example 69 in 1,4-dioxane (30 mL) The compound (800 mg), tert-butyl carbamate (380 mg), cesium carbonate (2.1 g) and 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (150 mg) were added, and after substitution with nitrogen, acetic acid Palladium (19 mg) was added and stirred in a sealed tube at 100 ° C. for 3 hours. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure.
- Example 71 7-[(tert-butoxycarbonyl) amino] -2-oxo-1-phenyl-1,2-dihydroquinoline-3-carboxylic acid Conducted using the compound prepared in Example 70 (880 mg). The title compound (650 mg) having the following physical data was obtained by subjecting it to the same intended operation as in Example 12.
- Example 72 Di-tert-butyl [3-( ⁇ 5-[(6,7-dimethoxyquinolin-4-yl) oxy] pyridin-2-yl ⁇ carbamoyl) -2-oxo-1-phenyl-1, 2,3,4-Tetrahydroquinolin-7-yl] imide dicarbonate Using the compound (100 mg) prepared in Example 71 and the compound (140 mg) prepared in Example 2, the same purpose as in Example 3 To give the title compound (190 mg) having the following physical property values. MS (M + H): 660
- Example 73 7-amino-N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2-oxo-1-phenyl-1,2-dihydro-3-quinoline Carboxamide
- the title compound (150 mg) having the following physical data was obtained by subjecting the compound (190 mg) produced in Example 72 to the same intended operation as in Example 25.
- Example 73 (1) 7-amino-N- ⁇ 5-[(7-methoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -2-oxo-1-phenyl-1,2-dihydro-3- Quinolinecarboxamide (LC-MS / ELSD): (retention time: 0.78 min); 1 H-NMR (CDCl 3 ): ⁇ 4.01, 4.23, 5.80, 6.54, 6.62, 7.53-7.67, 7.54-7.67, 8.22, 8.29, 8.54, 8.69, 8.95, 12.50.
- Biological Experimental Example 1 Measurement of Axl inhibitory activity (in vitro test) The measurement of the Axl enzyme inhibitory activity was performed by LanthaScreen (registered trademark) system (Invitrogen) according to the attached instructions. The reagents used are shown below.
- Reaction buffer A solution containing 50 mmol / L HEPES (pH 7.5), 0.01% Brij35, 10 mmol / L MgCl 2 and 1 mmol / L EGTA was prepared using purified water.
- Test substance solution A DMSO solution of each concentration of a test compound was diluted 20 times with a reaction buffer to prepare a solution containing a test compound having a concentration 5 times the final concentration.
- Enzyme solution A solution containing 400 ng / mL Axl enzyme was prepared using a reaction buffer.
- Substrate solution A solution containing 45 ⁇ mmol / L ATP and 500 nmol / L Fluorescein-Poly GT (Invitrogen) was prepared using a reaction buffer.
- Detection solution A solution containing 20 mM EDTA and 4 nM PY20 (Invitrogen) was prepared using Dilution B (Invitrogen).
- a DMSO solution of 10 mmol / L of the test compound was dispensed into a 96-well plate (Nunc), and a 3-fold common ratio dilution series was prepared with DMSO.
- a reaction buffer containing DMSO was added to the blank group and the medium group, and 5 ⁇ L of the test substance solution was added to the test substance group.
- a reaction buffer was added to the Blank group, and 10 ⁇ L of each well was added to the medium group and the test compound group, followed by stirring at room temperature for 10 minutes. After completion of the stirring, 10 ⁇ L of the substrate solution was added to each well and stirred for 1 hour at room temperature under light shielding.
- TR-FRET time-resolved fluorescence resonance energy transfer
- the value of 50% inhibition rate (IC50 value) of the test compound was calculated from an inhibition curve based on the inhibition rate at each concentration of the test compound.
- the IC50 values of the compounds of Example 21, Example 42, Example 66, Example 73, Example 28 and Example 36 are 0.0015 ⁇ M, 0.0035 ⁇ M, 0.0015 ⁇ M, 0.004 ⁇ M, 0.0013 ⁇ M and 0.0015 ⁇ M.
- Comparative compound A Biological Example 2 Measurement of growth inhibition rate using mouse pro-B cell line stably expressing Axl (Ba / F3 Axl) A 0.1 mmol / L test compound in DMSO was dispensed into a 96-well plate, Further, a dilution series having a common ratio of 3 times was prepared with DMSO. A DMSO solution of each concentration of the test compound was further diluted 500 times with RPMI 1640 medium (containing 10% HI-FBS and 1% penicillin) to prepare a test compound dilution solution containing the test compound at a concentration 500 times the final concentration.
- RPMI 1640 medium containing 10% HI-FBS and 1% penicillin
- RPMI medium for the Blank group In each well of a 96-well plate for measurement (BD Bioscience), RPMI medium for the Blank group, RPMI medium containing 0.2% DMSO for the medium group, and 50 ⁇ L each of the test compound dilution solution for the test compound group Added.
- Ba / F3 Axl was diluted with a medium to a density of 2 ⁇ 10 5 cells / mL to prepare a cell suspension.
- RPMI medium is added to the Blank group, and 50 ⁇ L of the cell suspension is added to the vehicle group and the test compound group, and the plate is allowed to stand at 37 ° C. and 5% CO 2 for 48 hours. did.
- RLU relative light unit
- the value of 50% inhibition rate (IC50 value) of the test compound was calculated from an inhibition curve based on the inhibition rate at each concentration of the test compound.
- the IC50 values of the compounds of Example 21, Example 42, Example 66, Example 73, Example 28 and Example 36 are 0.00096 ⁇ M, 0.0042 ⁇ M, 0.0057 ⁇ M, 0.00076 ⁇ M, 0.00099 ⁇ M and 0.00047 ⁇ M.
- Comparative Compound A was> 10 ⁇ M.
- Biological Example 3 Evaluation of kinase selectivity (in vitro test) In the same manner as in Biological Example 1, the value of the 50% inhibition rate (IC50 value) of the test compound against KDR kinase was measured. The Axl selective inhibitory activity against KDR of the test compound was calculated based on the ratio of the IC50 values and was as shown in Table 1 below.
- the test compound the compound of the present invention was used in Example 21, Example 42, Example 66, and Example 28, and the comparative compound was the compound of Example 74 described in Patent Document 5 (Comparative Compound B) having the following structure, And the compound of Example 92 (Comparative Compound C) was used.
- KDR is a kinase also called vascular endothelial growth factor receptor type 2 (VEGF Receptor 2), and it is known that inhibition of KDR may cause a side effect of increasing blood pressure (Hypertension, Vol. 39, 1095-1100 pages, 2002). Therefore, it was suggested that the compound of the present invention is an excellent compound that can avoid side effects such as hypertension that are concerned with the comparative compound.
- VEGF Receptor 2 vascular endothelial growth factor receptor type 2
- Biological Example 4 Determination of inhibitory activity of drug metabolizing enzyme (human CYP2C8 inhibitory action) The reaction was performed on a 384 well plate.
- the positive control substance (CYP2C8: quercetin) was adjusted to a final concentration of 300 times with DMSO (CYP2C8: 22.5 and 225 ⁇ mol / L), and a solution diluted 75 times with purified water containing 2.7% acetonitrile was prepared (CYP2C8). : 0.3 and 3 ⁇ mol / L).
- the test compound was adjusted to 0.3 and 3 mmol / L with DMSO, diluted 75-fold with purified water containing 2.7% acetonitrile, and adjusted to 4 and 40 ⁇ mol / L.
- potassium phosphate buffer pH 7.4
- magnesium chloride 5 mol / L
- substrate CYP2C8: Luciferin-ME, 150 ⁇ mol / L
- E. coli expression system liver microsomal CYP2C8 (Cypex, 30 pmol / L) were added.
- the reaction mixture was prepared (numerical values are final concentrations). 8 ⁇ L of this reaction mixture, 4 ⁇ L of the test compound and positive control substance solution prepared above, and NADPH production system solution (5.2 mM NADP, 13.2 mM glucose 6-phosphate, 1.6 U / mL glucose 6-phosphate dehydrogenase) were added to each well. The reaction was started by adding 4 ⁇ L and incubated at 37 ° C.
- the inhibition rate was calculated as the rate of decrease in luminescence intensity (inhibition rate) when compared with a control in which DMSO was added instead of the test compound solution and reacted.
- the IC50 value is ⁇ 1 ⁇ M when the inhibition rate is 50% or more at 1 ⁇ mol / L and> 10 ⁇ M when the inhibition rate is 50% or less at 10 ⁇ mol / L, and during that time (less than 50% at 1 ⁇ mol / L and 10 ⁇ mol / L) (In the case of 50% or more) was calculated by the following formula.
- the IC50 value of the compound of the present invention was measured by the above measuring method.
- the IC50 values of CYP2C8 were both> 10 ⁇ M. Therefore, it was found that the compound of the present invention has a low CYP inhibitory action.
- Formulation Example 1 The following components were mixed by a conventional method and then tableted to obtain 10,000 tablets each containing 10 mg of the active ingredient. N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl ⁇ -3,8-dioxo-2-phenyl-2,3,5,6,7,8-hexahydro- 4-isoquinolinecarboxamide ... 100g ⁇ Carboxymethylcellulose calcium (disintegrant): 20g ⁇ Magnesium stearate (lubricant): 10g ⁇ Microcrystalline cellulose: 870 g
- Formulation Example 2 The following components were mixed by a conventional method, filtered through a dust removal filter, filled in 5 ml aliquots, and sterilized by heating in an autoclave to obtain 10,000 ampoules containing 20 mg of active ingredient per ampoule.
- the compound of the present invention has potent Axl inhibitory activity, it is useful for the treatment of Axl-related diseases such as cancer, kidney disease, immune system disease, and circulatory system disease.
Abstract
Description
[1] 一般式(I)
ここで、R1で表されるC1~8アルキル基が分枝鎖アルキル基の場合、同一の炭素原子から分枝したC1~3アルキル基は一緒になってC3~7の飽和炭素環を形成してもよく、
R2は(1)1~5個のR21で置換されていてもよいC1~8アルキル基、(2)1~5個のR22で置換されていてもよいC2~8アルケニル基、(3)1~5個のR23で置換されていてもよいC2~8アルキニル基、(4)-OR24基、(5)1~5個のR25で置換されていてもよいC3~7の炭素環、(6)1~5個のR26で置換されていてもよい4~7員のヘテロ環、(7)ハロゲン原子、(8)C(O)R27基、または(9)C(O)NR28R29基を表し、
ここで、mが2以上であり、R2が隣り合う炭素原子上にあり、かつR2がアミノ基で置換されていてもよいC1~3アルキル基、またはアミノ基で置換されていてもよいC2~3アルケニル基を表すとき、隣り合う炭素原子に結合するR2は当該炭素原子と一緒になって、1~3個のR20で置換されていてもよい5~7員の環状基を形成してもよく、このとき、R1がC1~3アルキル基を表すとき、当該複数のR2によって形成された5~7員の環状基上の原子と一緒になって、さらに5~7員の環状基を形成してもよく、
R3は(1)C1~4アルキル基、(2)ハロゲン原子、(3)C1~4ハロアルキル基、または(4)-OR31基を表し、
R4は(1)C1~4アルコキシ基、(2)C1~4ハロアルキル基、(3)-OR41基、(4)C1~4アルキル基、(5)C2~4アルケニルオキシ基、または(6)C2~4アルキニルオキシ基を表し、
R11は(1)-OR101基、(2)SO2R102基、(3)NR103R104基、または(4)1~3個のハロゲン原子で置換されていてもよいC3~7の炭素環を表し、
R12は(1)アミノ基で置換されていてもよいC1~4アルキル基、(2)C1~4ハロアルキル基、(3)ハロゲン原子を表し、
R13は(1)アミノ基で置換されていてもよいC1~4アルキル基、(2)C1~4ハロアルキル基、(3)ハロゲン原子を表し、
R101は(1)水素原子、または(2)C1~4アルキル基を表し、
R102は(1)水素原子、または(2)C1~4アルキル基を表し、
R103およびR104はそれぞれ独立して、(1)水素原子、または(2)C1~4アルキル基を表し、
R20は(1)C1~4アルキル基、(2)ハロゲン原子、(3)C1~4ハロアルキル基、(4)オキソ基、(5)-OR201基、(6)COOR205基、(7)NR206R207基、または(8)COR208基を表し、ここで、2個のR20がC1~3アルキル基を表し、かつ同一の炭素原子上にあるとき、当該R20は一緒になってC3~7の飽和炭素環を形成してもよく、
R21、R22、およびR23はそれぞれ独立して、(1)ハロゲン原子、(2)-OR202基、または(3)NR203R204基を表し、
R24は(1)水素原子、(2)C1~4アルキル基、または(3)4~10員のヘテロ環を表し、
R25およびR26はそれぞれ独立して、(1)C1~4アルキル基、または(2)ハロゲン原子を表し、
R27は(1)水素原子、(2)C1~4アルキル基、または(3)C3~7の炭素環を表し、
R28およびR29はそれぞれ独立して、(1)水素原子、(2)C1~4アルキル基、または(3)C3~7の炭素環を表し、
R201は(1)水素原子、または(2)C1~4アルキル基を表し、
R202は(1)水素原子、または(2)C1~4アルキル基を表し、
R203およびR204はそれぞれ独立して、(1)水素原子、(2)C1~4アルキル基、(3)C(O)R210基、または(4)COOR217基を表し、
R205は(1)水素原子、または(2)C1~4アルキル基を表し、
R206およびR207はそれぞれ独立して、(1)水素原子、または(2)C1~4アルキル基を表し、
R208は(1)水素原子、(2)C1~4アルキル基、(3)C2~4アルケニル基、または(4)C2~4アルキニル基を表し、
R210は(1)NR211R212またはシアノ基で置換されていてもよいC1~4アルキル基、(2)NR213R214またはシアノ基で置換されていてもよいC2~4アルケニル基、または(3)NR215R216またはシアノ基で置換されていてもよいC2~4アルキニル基を表し、
R211、R212、R213、R214、R215、R216およびR217はそれぞれ独立して、(1)水素原子、または(2)C1~4アルキル基を表し、
R31は(1)水素原子、(2)C1~4アルキル基、または(3)C1~4ハロアルキル基を表し、
R41は、(1)水素原子、(2)(a)(i)C1~4アルキル基、(ii)C1~4ハロアルキル基、および(iii)ハロゲン原子からなる群から選択される1~2個の置換基で置換されていてもよい5~7員の環状基、(b)NR401R402、(c)水酸基、および(d)SO2R403基からなる群から選択される1~2個の置換基で置換されたC1~8アルキル基、(3)(a)(i)C1~4アルキル基、(ii)C1~4ハロアルキル基、および(iii)ハロゲン原子からなる群から選択される1~2個の置換基で置換されていてもよい5~7員の環状基、(b)NR401R402、(c)水酸基、および(d)SO2R403基からなる群から選択される1~2個の置換基で置換されたC2~8アルケニル基、または(4)(a)(i)C1~4アルキル基、(ii)C1~4ハロアルキル基、および(iii)ハロゲン原子からなる群から選択される1~2個の置換基で置換されていてもよい5~7員の環状基、(b)NR401R402、(c)水酸基、および(d)SO2R403基からなる群から選択される1~2個の置換基で置換されたC2~8アルキニル基を表し、
R401およびR402はそれぞれ独立して、(1)水素原子、または(2)C1~4アルキル基を表し、
R403は(1)水素原子、または(2)C1~4アルキル基を表し、
Aは(1)CH、または(2)窒素原子を表し、
Lは(1)-O-、(2)-NH-、(3)-C(O)-、(4)-CR6R7-、(5)-S-、(6)-S(O)-、または(7)-S(O)2-を表し、
R6およびR7はそれぞれ独立して、(1)水素原子、(2)ハロゲン原子、(3)C1~4アルキル基、(4)水酸基、または(5)NH2を表し、
ring1は5~7員の環状基を表し、
R11、R12、R13、R20、R21、R22、R23、R25、またはR26は、いずれも複数のとき、同じでも異なっていてもよく、
mは0~3の整数を表し、
nは0~3の整数を表し、
qは0~4の整数を表し、
mが2以上のとき、複数のR2は同じでも異なっていてもよく、
nが2以上のとき、複数のR3は同じでも異なっていてもよく、
qが2以上のとき、複数のR4は同じでも異なっていてもよく、
ただし、式
[2] R2が(1)1~5個のR21で置換されていてもよいC1~8アルキル基、(2)1~5個のR22で置換されていてもよいC2~8アルケニル基、(3)1~5個のR23で置換されていてもよいC2~8アルキニル基、(4)ハロゲン原子、または(5)C(O)R27基である前記[1]記載の化合物、
[3] 一般式(I)中、式
[4] ring1がベンゼン、またはピリジンである前記[1]~[3]のいずれかに記載の化合物、
[5] Lが(1)-O-、(2)-NH-、または(3)-C(O)-である前記[1]~[4]のいずれかに記載の化合物、
[6] (1)5-アセチル-N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-6-メチル-2-オキソ-1-フェニル-1,2-ジヒドロ-3-ピリジンカルボキサミド、(2)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-3,8-ジオキソ-2-フェニル-2,3,5,6,7,8-ヘキサヒドロ-4-イソキノリンカルボキサミド、(3)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-2,5-ジオキソ-1-フェニル-2,5,6,7,8,9-ヘキサヒドロ-1H-ピリド[3,2-c]アゼピン-3-カルボキサミド、(4)7-アミノ-N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-2-オキソ-1-フェニル-1,2-ジヒドロ-3-キノリンカルボキサミド、(5)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-2-オキソ-1-フェニル-1,2-ジヒドロ-1,7-ナフチリジン-3-カルボキサミド、または(6)7-(2-ブチノイル)-N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-2-オキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-1,7-ナフチリジン-3-カルボキサミドである前記[1]記載の化合物、
[7] 前記[1]記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド体、またはそれらのプロドラッグを含有してなる医薬組成物、
[8] Axl阻害剤である前記[7]記載の医薬組成物、
[9] Axl関連疾患の予防および/または治療剤である前記[7]記載の医薬組成物、
[10] Axl関連疾患が、癌、腎臓疾患、免疫系疾患、または循環器系疾患である前記[9]記載の医薬組成物、
[11] 癌が、急性骨髄性白血病、慢性骨髄性白血病、急性リンパ性白血病、慢性リンパ性白血病、多発性骨髄腫、メラノーマ、乳癌、膵臓癌、神経膠腫、食道腺癌、大腸癌、腎細胞癌、甲状腺癌、非小細胞肺癌、前立腺癌、胃癌、肝癌、ブドウ膜悪性黒色腫、卵巣癌、子宮内膜癌、リンパ腫、頭頸部癌、または肉腫である前記[10]記載の医薬組成物、
[12] 癌細胞の転移抑制剤である前記[7]記載の医薬組成物、
[13] 前記[1]記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド、またはそれらのプロドラッグの有効量を哺乳動物に投与することを特徴とする、Axl関連疾患の予防および/または治療方法、
[14] Axl関連疾患の予防および/または治療のための前記[1]記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド、またはそれらのプロドラッグ、および
[15] Axl関連疾患の予防および/または治療剤を製造するための前記[1]記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド、またはそれらのプロドラッグの使用等に関する。
本発明においては、特に指示しない限り異性体はこれをすべて包含する。例えば、アルキル基には直鎖のものおよび分枝鎖のものが含まれる。さらに、二重結合、環、縮合環における幾何異性体(E体、Z体、シス体、トランス体)、不斉炭素原子の存在等による光学異性体(R、S体、α、β配置、エナンチオマー、ジアステレオマー)、旋光性を有する光学活性体(D、L、d、l体)、クロマトグラフ分離による極性体(高極性体、低極性体)、平衡化合物、回転異性体、これらの任意の割合の混合物、ラセミ混合物は、すべて本発明に含まれる。また、本発明においては、互変異性体による異性体をもすべて包含する。
本発明化合物は、公知の方法、例えば、Comprehensive Organic Transformations : A Guide to Functional Group Preparations, 2nd Edition (Richard C. Larock, John Wiley & Sons Inc, 1999)に記載された方法、または実施例に示す方法等を適宜改良し、組み合わせて用いることで製造することができる。
(1)酸ハライドを用いる方法、
(2)混合酸無水物を用いる方法、
(3)縮合剤を用いる方法等が挙げられる。
(1)酸ハライドを用いる方法は、例えば、カルボン酸を有機溶媒(クロロホルム、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン等)中または無溶媒で、酸ハライド化剤(オキザリルクロライド、チオニルクロライド等)と-20℃~還流温度で反応させ、得られた酸ハライドを塩基(ピリジン、トリエチルアミン、ジメチルアニリン、ジメチルアミノピリジン、ジイソプロピルエチルアミン等)の存在下、アミンと有機溶媒(クロロホルム、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン等)中、0~40℃の温度で反応させることにより行なわれる。また、得られた酸ハライドを有機溶媒(ジオキサン、テトラヒドロフラン等)中、アルカリ水溶液(重曹水または水酸化ナトリウム溶液等)を用いて、アミンと0~40℃で反応させることにより行なうこともできる。
(1)アルカリ加水分解による脱保護反応は、例えば有機溶媒(例えば、メタノール、テトラヒドロフラン、ジオキサン等)中、アルカリ金属の水酸化物(例えば、水酸化ナトリウム、水酸化カリウム、水酸化リチウム等)、アルカリ土類金属の水酸化物(例えば、水酸化バリウム、水酸化カルシウム等)または炭酸塩(例えば、炭酸ナトリウム、炭酸カリウム等)あるいはその水溶液もしくはこれらの混合物を用いて、0~40℃で行なわれる。
本発明化合物の毒性は十分に低いものであり、医薬品として安全に使用することができる。
本発明化合物は、Axl阻害活性を有するので、哺乳動物、特にヒトにおいて、Axl関連疾患の予防および/または治療剤として使用することができる。
1)その化合物の予防および/または治療効果の補完および/または増強、
2)その化合物の動態・吸収改善、投与量の低減、および/または
3)その化合物の副作用の軽減のために他の薬物と組み合わせて、併用薬として投与してもよい。
{カラム:Waters ACQUITY C18(粒子径:1.7 x 10-6 m;カラム長:30 x 2.1 mm I.D.);流速:1.0mL/min;カラム温度:40℃;移動相(A):0.1%ギ酸水溶液;移動相(B):0.1%ギ酸-アセトニトリル溶液;グラジエント(移動相(A):移動相(B)の比率を記載):[0分]95:5;[0.1分]95:5;[1.2分]5:95;[1.4分]5:95;[1.41分]95:5;[1.5分]95:5;検出器:UV(PDA)、ELSD、MS}
で行った。
窒素気流下、2Lの4つ口フラスコに、4-クロロ-6,7-ジメトキシキノリン(39g)(CAS登録番号:35654-56-9)のクロロベンゼン(400mL)溶液、6-クロロピリジン-3-オール(25g)、4-ジメチルアミノピリジン(DMAP)(64g)を加え、バス温(140℃)で42時間撹拌した。室温まで放冷した後、水(700mL)、酢酸エチル(1L)を加えて、分液した。水層を酢酸エチル(1L)で再度抽出し、合わせた有機層を飽和食塩水(500mL)で洗浄、無水硫酸ナトリウムで乾燥させた。溶媒を減圧留去し、得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=1:8)で精製し、下記物性値を有する標題化合物(28g)を得た。
TLC:Rf 0.22 (ヘキサン:酢酸エチル=1:3);
1H-NMR (DMSO-d6):δ 8.52, 8.48, 7.87 - 7.85, 7.66, 7.49, 7.43, 6.65, 3.95, 3.93。
窒素気流下、2Lの4つ口フラスコに、実施例1で製造した化合物(28g)のテトラヒドロフラン(THF)(500mL)溶液、1.3mol/Lのリチウムビス(トリメチルシリル)アミド(LHDMS)(100mL)、トリス(ジベンジリデンアセトン)ジパラジウム(0)クロロホルム錯体(4.6g)、2-ジシクロヘキシルホスフィノ-2’,6’-ジメトキシビフェニル(4.4g)を加え、バス温(80℃)で2時間撹拌した。さらに6mol/Lの塩酸(250mL)を加え、バス温(80℃)で2時間撹拌した。室温まで放冷後、セライトろ過(酢酸エチル2Lで洗浄)し、飽和重炭酸水素ナトリウム水溶液(2L)を加えて分液した。水層を酢酸エチル(1L)で再度抽出し、合わせた有機層を飽和食塩水 (500mL)で洗浄、無水硫酸ナトリウムで乾燥させた。溶媒を減圧留去し、得られた残渣をシリカゲルカラムクロマトグラフィー(酢酸エチル→酢酸エチル:メタノール=9:1)で精製し、下記物性値を有する標題化合物(22g)を得た。
TLC:Rf 0.51 (酢酸エチル:メタノール=4:1);
1H-NMR (DMSO-d6):δ 8.45, 7.89, 7.51, 7.38 - 7.36, 6.56, 6.42, 6.05, 3.94。
室温において2-オキソ-1-フェニル-1,2-ジヒドロピリジン-3-カルボン酸(CAS登録番号:868171-81-7)(1.9g)、O-(7-アザ-1-ベンゾトリアゾリル)-N,N,N’,N’-テトラメチルウロニウム ヘキサフルオロホスフェート(HATU)(4.1g)をN,N-ジメチルホルムアミド(DMF)(50mL)に溶解し、ジイソプロピルエチルアミン(DIPEA)(2.3g)、実施例2で製造した化合物(2.7g)を加え、21時間撹拌した。反応溶液に水を加え、固体を析出させた。ろ過によって得られた固体をエタノールで洗浄し、減圧乾燥することで、下記物性値を有する標題化合物(3.6g)を得た。
TLC:Rf 0.54 (酢酸エチル:メタノール=9:1);
1H-NMR (CDCl3):δ 4.05, 6.46, 6.59, 7.41-7.44, 7.51-7.57, 7.68, 8.26, 8.48, 8.51, 8.74, 12.40。
実施例2で製造した化合物、および2-オキソ-1-フェニル-1,2-ジヒドロピリジン-3-カルボン酸の代わりに相当するカルボン酸誘導体を用いて、実施例3と同様の目的の操作に付すことにより、下記の実施例化合物を得た。
実施例3(1):N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-5-オキソ-2,3-ジヒドロ-1H,5H-ピリド[3,2,1-ij]キノリン-6-カルボキサミド
TLC:Rf 0.66 (酢酸エチル:メタノール=5:1);
1H-NMR (CDCl3):δ 2.11, 3.00, 3.94, 4.23, 6.56, 7.32, 7.41, 7.54, 7.60, 7.87-7.94, 8.41-8.50, 9.04, 12.76。
TLC:Rf 0.64 (酢酸エチル:メタノール=19:1);
1H-NMR (CDCl3):δ 2.05, 2.81, 4.05, 6.26, 6.43, 7.22, 7.42, 7.49-7.59, 8.21, 8.41, 8.49, 12.50。
5-アセチル-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-カルボン酸(CAS登録番号:88302-06-1)(450mg)をメタノール(20mL)に溶解させ、0℃で塩化オキサリル(0.43mL)を滴下し、室温で3時間撹拌した。反応溶液を減圧濃縮し、得られた残渣に飽和炭酸水素ナトリウムを加え、ジクロロメタンで抽出した。有機層を硫酸ナトリウムで乾燥させ、ろ過した後、減圧濃縮することにより、下記物性値を有する標題化合物(400mg)を得た。
1H-NMR (CDCl3):δ 2.54, 2.79, 3.94, 8.72, 12.34。
ジクロロメタン(10mL)に、実施例4で製造した化合物(500mg)、フェニルホウ酸(580mg)、ジアセトキシ銅(II)(870mg)、ピリジン(5.0mL)および4Åモレキュラーシーブス(1.0g)を加えて、酸素雰囲気下、室温で48時間撹拌した。反応溶液をセライトろ過し不溶固体を除去した後、ジクロロメタン(200mL)を加えて希釈し、有機層を水洗した。得られた有機層を硫酸ナトリウムで乾燥させ、ろ過した後、減圧濃縮により溶媒を留去した。得られた残渣に、THF(20mL)、メタノール(1mL)、(1mL)および水酸化リチウム一水和物(91mg)を加えて室温で16時間撹拌させた。反応液に1mol/L塩酸を加え、有機層をジクロロメタンで抽出し(3×50mL)、硫酸マグネシウムで乾燥させてろ過した後、減圧濃縮することで下記物性値を有する標題化合物(46mg)を得た。
1H-NMR (CDCl3):δ 2.45, 2.64, 7.17-7.20, 7.57-7.64, 8.98, 13.44。
(LC-MS/ELSD):(保持時間:0.81分);
1H-NMR (CDCl3):δ 2.45, 2.67, 4.04, 4.05, 6.46, 7.21, 7.42, 7.53-7.64, 8.24, 8.46, 8.51, 9.12, 12.04。
アルゴン雰囲気下、4-クロロ-6,7ジメトキシキナゾリン(CAS登録番号: 13790-39-1)(8.0g)、6-クロロピリジン-3-オール(4.6g)のDMSO懸濁液(20mL)にDMAP(4.4g)を加えてバス温(80℃)にて2時間加熱撹拌した。室温まで放冷後、酢酸エチルで反応液を希釈し、水、飽和炭酸水素ナトリウム水溶液で洗浄した。有機層を無水硫酸ナトリウムで乾燥後、濃縮し、得られた残渣をヘキサン-酢酸エチル(3:1)で洗浄し、下記物性値を有する標題化合物(9.1g)を得た。
TLC:Rf 0.16 (ヘキサン:酢酸エチル=1:1);
1H-NMR (DMSO-d6):δ 3.97, 3.99, 7.41, 7.58, 7.69, 7.97, 8.50, 8.57。
アルゴン雰囲気下、実施例7で製造した化合物(1.0g)のTHF溶液(15mL)に1.0mol/LのLHDMS(4.7mL)、トリス(ジベンジリデンアセトン)ジパラジウム(0)クロロホルム錯体(140mg)、2-ジシクロヘキシルホスフィノ-2’,6’-ジメトキシビフェニル(170mg)を加え、バス温(70℃)で4時間撹拌した。反応液を室温まで放冷後、氷水にあけ、酢酸エチルで抽出した。有機層を水で洗浄後、無水硫酸ナトリウムで乾燥し、濃縮した。得られた残渣をアセトニトリル(30mL)に懸濁し、2.0mol/Lの塩酸(10mL)を加えて室温で30分撹拌した。反応液中に生じた析出物をろ取し、下記物性値を有する標題化合物(1590mg)を得た。
TLC:Rf 0.16 (酢酸エチル:メタノール=10:1);
1H-NMR (DMSO-d6):δ 3.96, 3.99, 4.24, 7.10, 7.42, 7.53, 8.00-8.20, 8.07, 8.20, 8.61。
(LC-MS/ELSD):(保持時間:0.95分);
1H-NMR (CDCl3):δ 2.45, 2.68, 4.07, 7.19-7.23, 7.33, 7.54, 7.55-7.65, 7.68, 8.28, 8.48, 8.61, 9.12, 12.02。
ジクロロメタン(60mL)に、2,2-ジメチルプロピル 5-ブロモ-2-ヒドロキシピリジン-3-カルボキシラート(2.0g)を用いて、フェニルホウ酸(1.7g)、ジアセトキシ銅(II)(5.2g)、およびピリジン(15mL)を加えて、酸素雰囲気下、室温で16時間撹拌した。反応溶液をセライトろ過し不溶固体を除去した後、ジクロロメタンを加えて希釈し、有機層を水および1mol/L塩酸で洗浄した。得られた有機層を硫酸ナトリウムで乾燥させ、ろ過した後、減圧濃縮により溶媒を留去し、下記物性値を有する標題化合物(1.5g)を得た。
MS (M+H):364。
実施例10で製造した化合物(100mg)をアセトニトリル(10mL)に溶解させ、2-メチル-3-ブチン-2-オール(51mg)、トリス(tert-ブチル)ホスフィン(1.0mL)、テトラキス(トリフェニルホスフィン)パラジウム(0)(32mg)、ヨウ化銅(I)(3.0mg)およびトリエチルアミン(0.2mL)を加えて、70℃で16時間撹拌した。反応溶液を氷水にあけ、酢酸エチルで抽出した。有機層を硫酸ナトリウムで乾燥し、ろ過した後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=100:0→30:70)によって精製することにより、下記物性値を有する標題化合物(55mg)を得た。
1H-NMR (CDCl3):δ 1.02, 1.58, 4.01, 7.26-7.38, 7.44-7.49, 7.71, 8.14。
実施例11で製造した化合物(50mg)をメタノール/水の混合溶媒(4:1、3.5mL)、に溶解させ、水酸化リチウム一水和物(4.0mg)を加えて室温で16時間撹拌させた。反応液に1N塩酸を加え、有機層をジクロロメタンで抽出し、硫酸マグネシウムで乾燥させてろ過した後、減圧濃縮することで下記物性値を有する標題化合物(32mg)を得た。
1H-NMR (CDCl3):δ 1.59, 7.38-7.41, 7.54-7.59, 7.83, 8.60, 13.74。
実施例12で製造した化合物(25mg)および実施例2で製造した化合物(25mg)を用いて、実施例3と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(10mg)を得た。
(LC-MS/ELSD):(保持時間:0.77分);
1H-NMR (DMSO-d6):δ 1.47, 4.00, 4.02, 6.88, 7.54, 7.55-7.60, 7.70, 7.96, 8.34, 8.45-8.48, 8.72, 12.31。
実施例2で製造した化合物の代わりに相当するキノリン誘導体、および実施例12で製造した化合物を用いて、実施例3と同様の目的の操作に付すことにより、下記の実施例化合物を得た。
(LC-MS/ELSD):(保持時間:0.86分);
1H-NMR (CDCl3):δ 1.60, 2.00, 3.97, 6.43, 7.23, 7.38-7.44, 7.51-7.59, 7.81, 8.20-8.26, 8.46, 8.61, 8.71, 12.24。
(LC-MS/ELSD):(保持時間:0.80分);
1H-NMR (CDCl3):δ 1.61, 2.02, 3.97, 6.54, 7.39-7.43, 7.51-7.59, 7.81, 8.00, 8.26, 8.47, 8.55, 8.71, 12.25。
3-ブロモ-5-(トリフルオロメチル)ピリジン-2(1H)-オン(1.0g)を用いて、実施例10と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(1.1g)を得た。
1H-NMR (CDCl3):δ 7.36-7.39, 7.48-7.53, 7.75-7.77, 7.94。
実施例14で製造した化合物(250mg)をDMF(8.0mL)及びメタノール(8.0mL)の混合溶媒に溶解させ、反応容器内を窒素雰囲気下、10分間脱気した。酢酸パラジウム(II)(36mg)、1,1’-ビス(ジフェニルホスフィノ)フェロセン(88mg)およびトリエチルアミン(0.33mL)を加えて、一酸化炭素雰囲気下(100psi)、90℃で16時間撹拌した。反応溶液をセライトろ過し不溶固体を除去した後、ジクロロメタンを加えて希釈した。得られた溶液を10%クエン酸水溶液で洗浄し、得られた有機層を硫酸ナトリウムで乾燥させ、ろ過した後、減圧濃縮により溶媒を留去し、下記物性値を有する標題化合物(140mg)を得た。得られた化合物は精製することなく、次の反応に用いた。
1H-NMR (CDCl3):δ 3.93, 7.33-7.41, 7.45-7.58, 7.93-7.97, 8.35。
実施例15で製造した化合物(100mg)をTHF(2mL)に溶解させ、ナトリウムトリメチルシラノラート(38mg)を加えて、室温で3時間撹拌した。反応溶液をろ過し、得られた沈殿物をTHFで洗浄し、下記物性値を有する標題化合物(45mg)を得た。得られた化合物は精製することなく、次の反応に用いた。
MS (M+H):284。
実施例16で製造した化合物(60mg)および実施例2で製造した化合物(62mg)を用いて、実施例3と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(43mg)を得た。
(LC-MS/ELSD):(保持時間:0.84分);
1H-NMR (CDCl3):δ 4.05, 4.06, 6.47, 7.37-7.48, 7.50-7.65, 8.02-8.06, 8.27, 8.47, 8.51, 8.90, 12.08。
実施例2で製造した化合物の代わりに相当するキノリン誘導体、および実施例16で製造した化合物を用いて、実施例3と同様の目的の操作に付すことにより、下記の実施例化合物を得た。
(LC-MS/ELSD):(保持時間:0.93分);
1H-NMR (CD3OD):δ 3.97, 6.44, 7.19-7.25, 7.38-7.50, 7.53-7.67, 8.02-8.06, 8.22, 8.26, 8.47, 8.61, 8.90, 12.08。
(LC-MS/ELSD):(保持時間:0.88分);
1H-NMR (CDCl3):δ 3.96, 6.54, 7.39-7.44, 7.56-7.60, 8.00, 8.02-8.04, 8.27, 8.47, 8.56, 8.89, 12.07。
メチル 5-ブロモ-2-オキソ-1-フェニル-1,2-ジヒドロピリジン-3-カルボキシラート(CAS登録番号:381248-02-8)(100mg)、およびトリブチル(1-エトキシビニル)スズ(0.11mL)を1,4-ジオキサン(2mL)に溶解させ、パラジウム(0)テトラキス(トリフェニルホスフィン)(8mg)を加えて、封管中100℃で16時間撹拌した。反応溶液をセライトろ過した後、ろ液に水を加えて、酢酸エチルで抽出した。得られた有機層を水、次いで飽和食塩水で洗浄し、硫酸ナトリウムで乾燥させ、ろ過した後、減圧濃縮することで、下記物性値を有する標題化合物(270mg)を得た。
MS (M+H):300。
実施例18で製造した化合物(270mg)をTHF(5mL)に溶解させ、2mol/L塩酸(2mL)を加えて、室温で1時間撹拌した。反応溶液を減圧濃縮し、得られた残渣に水を加えて、酢酸エチルで抽出した。得られた有機層を飽和食塩水で洗浄し、硫酸ナトリウムで乾燥した後、減圧濃縮することで、下記物性値を有する標題化合物(80mg)を得た。
MS (M+H):272。
実施例19で製造した化合物(80mg)をTHF/水の混合溶媒(4:1、5mL)に溶解させ、水酸化リチウム一水和物(62mg)を加えて室温で16時間撹拌させた。反応液に1N塩酸を加え、有機層をジクロロメタンで抽出し、硫酸マグネシウムで乾燥させてろ過した後、減圧濃縮することで下記物性値を有する標題化合物(50mg)を得た。
1H-NMR (CDCl3):δ 2.59, 7.39-7.42, 7.58-7.62, 8.47, 9.07。
実施例20で製造した化合物(50mg)および実施例2で製造した化合物(50mg)を用いて、実施例3と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(17.5mg)を得た。
(LC-MS/ELSD):(保持時間:0.73分);
1H-NMR (CDCl3):δ 2.60, 4.05, 6.47, 7.53-7.60, 8.27, 8.46, 8.47, 8.49, 8.52, 9.20, 12.00。
室温において、tert-ブチル 2,4-ジオキソピペリジン-1-カルボキシラート(CAS登録番号:845267-78-9)(3.0g)をDMFに溶解し、tert-ブトキシカリウム(13g)、エチル (2E)-2-シアノ-3-エトキシプロパ-2-エノアート(CAS登録番号:94-05-3)(2.4g)を加え、21時間撹拌した。反応溶液を酢酸エチルで希釈し、2Nの塩酸水溶液を加え撹拌した。さらに酢酸エチル、水を加え有機層を抽出した。飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去し、下記物性値を有する標題化合物(3.5g)を得た。
1H-NMR (CDCl3):δ 1.19, 1.43, 2.27, 3.62, 4.09, 8.19。
室温において、実施例22で製造した化合物(66mg)をエタノール(1mL)に溶解し、アニリン(36mg)を加え、50℃で30分撹拌した。反応液中から析出した固体を桐山ロートでろ取、エタノールで洗浄し、得られた残渣を減圧乾燥することで、下記物性値を有する標題化合物(84mg)を得た。
1H-NMR (DMSO-d6):δ 1.46, 2.62, 3.82, 7.43, 7.56-7.62, 8.74, 13.33。
実施例23で製造した化合物(80mg)、および実施例2で製造した化合物(68mg)を用いて、実施例3と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(46mg)を得た。
TLC:Rf 0.40 (ヘキサン:酢酸エチル=1:2);
1H-NMR (CDCl3):δ 1.56, 2.67, 3.96, 4.04, 6.43, 7.24-7.27, 7.41, 7.52-7.62, 8.20, 8.46, 8.48, 9.39, 11.90。
TLC:Rf 0.35 (酢酸エチル,NHシリカ);
1H-NMR (DMSO-d6):δ 2.25, 2.71, 3.93, 3.94, 6.58, 7.40-7.62, 7.85, 7.96, 8.34, 8.42, 8.50, 8.97, 12.10。
300mLの3径ナスフラスコにアニリン(3.1g)、DMAP(0.61g)、トリエチルアミン(5.1mL)、ジクロロメタン(25mL)を加えた後、氷浴下においてエチルマロニルクロライド(5.0g)のジクロロメタン(25mL)溶液を20分かけて滴下した。そのまま30分間撹拌した後、水を加え、ジクロロメタンを減圧留去した。残渣を酢酸エチルで抽出した後、1N塩酸、飽和食塩水の順で洗浄し、無水硫酸ナトリウムで乾燥後、溶媒を減圧留去した。得られた残渣はシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=7:3→1:1)で精製し、下記物性値を有する標題化合物(5.8g)を得た。
TLC:Rf 0.50 (ヘキサン:酢酸エチル=1:1);
1H-NMR (CDCl3):δ 1.32, 3.47, 4.26, 7.13, 7.35, 7.55, 9.22。
実施例26で製造した化合物(560mg)をトルエン(10mL)に溶解させ、3-ブロモピリジン-4-カルボアルデヒド(500mg)、トリス(ジベンジリデンアセトン)ジパラジウム(0)(120mg)、4,5-ビス(ジフェニルホスフィノ)-9,9-ジメチルキサンテン(160mg)および炭酸セシウム(1800mg)を加えて、150℃で1時間撹拌した。反応溶液に水を加え、酢酸エチルで抽出した。有機層を硫酸ナトリウムで乾燥し、ろ過後、減圧濃縮した。得られた残渣をシリカゲルクロマトグラフィー(酢酸エチル)にて精製することにより、下記物性値を有する標題化合物(250mg)を得た。
TLC:Rf 0.23 (ヘキサン:酢酸エチル=1:1);
1H-NMR (CDCl3):δ 1.41, 4.43, 7.29-7.33, 7.52-7.65, 8.13, 8.41, 8.47。
TLC:Rf 0.75 (ジクロロメタン:メタノール=9:1);
1H-NMR (DMSO-d6):δ 3.98, 3.99, 6.61, 7.45, 7.57, 7.59-7.79, 7.95, 8.03, 8.16, 8.44, 8.50, 8.54, 8.61, 9.26, 12.34。
1,7-ナフチリジン-2(1H)-オン(CAS登録番号:54920-82-0)(900mg)にエタノール(20mL)、ベンジルブロマイド(0.8mL)を加え、80℃で18時間加熱撹拌した。0℃に冷却後、水素化ホウ素ナトリウム(1100mg)を加え、10分間0℃にて撹拌後、塩酸を加え90分室温にて撹拌した。水酸化ナトリウムで中和後、酢酸エチルを加え、有機層を抽出した。有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。その後、得られた固体を酢酸エチルで洗浄することにより、下記物性値を有する標題化合物(900mg)を得た。
1H-NMR (CD3OD):δ 2.66, 2.80, 3.45, 3.75, 6.40, 7.29-7.44。
実施例29で製造した化合物(800mg)をメタノール(10mL)に溶解し、トリフルオロ酢酸(0.27mL)、パラジウムカーボン(160mg)を加え、水素ガス雰囲気下、室温にて5時間撹拌した。反応溶液をセライトろ過後、溶媒を減圧留去することにより、下記物性値を有する標題化合物(800mg)を得た。
1H-NMR (CD3OD):δ 2.89, 3.51, 4.21, 6.53, 7.48。
実施例30で製造した化合物(800mg)をTHF(10mL)に溶解し、トリエチルアミン(1.3mL)、二炭酸ジ-tert-ブチル(0.85mL)を加え室温にて3時間撹拌した。反応溶液に水を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。その後、得られた固体をメチルtert-ブチルエーテル(MTBE)溶媒で洗浄することにより、下記物性値を有する標題化合物(760mg)を得た。
(LC-MS/ELSD):(保持時間:0.70分);
1H-NMR (CD3OD):δ 1.52, 2.61, 3.66, 4.43, 6.42, 7.43。
実施例31で製造した化合物(490mg)をDMF(5mL)に溶解し、N-ブロモスクシンイミド(360mg)を加え室温にて2時間撹拌した。反応溶液を酢酸エチルで希釈し、水を加え有機層を抽出した。有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去することにより、下記物性値を有する標題化合物(560mg)を得た。
TLC:Rf 0.17(酢酸エチル:メタノール=10:1);
1H-NMR (CD3OD):δ 1.52, 2.61, 3.65, 4.39, 7.83。
実施例32で製造した化合物(1400mg)を用いて、実施例10→実施例14と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(96mg)を得た。
(LC-MS/ELSD):(保持時間:1.01分);
TLC:Rf 0.54(ヘキサン:酢酸エチル=1:1)。
実施例33で製造した化合物を実施例12と同様の目的の操作に付すことにより製造した化合物(30mg)および実施例2で製造した化合物(17mg)を用いて、実施例3と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(29mg)を得た。
TLC:Rf 0.83(酢酸エチル:メタノール=10:1,NHシリカ);
(LC-MS/ELSD):(保持時間:0.95分)。
実施例34で製造した化合物(25mg)を用いて、ジクロロメタン(1mL)に溶解させ、トリフルオロ酢酸(0.03mL)を加えて、室温で3時間撹拌した。反応溶液を減圧濃縮することで、下記物性値を有する標題化合物(28mg)を得た。
TLC:Rf 0.56(ジクロロメタン:メタノール:28%アンモニア水=9:1:0.1);
(LC-MS/ELSD):(保持時間:0.69分)。
TLC:Rf 0.42 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 1.89 (2.05), 2.82 (2.88), 3.85 (3.99), 4.05, 4.23 (4.37), 6.44, 7.24-7.33, 7.42, 7.52-7.66, 8.23, 8.42-8.54, 12.33 (12.34)(回転異性体の混合物として観測された)。
氷浴下、シクロヘキサン-1,3-ジオン(CAS登録番号:504-02-9)(5.0g)のジクロロメタン(230mL)溶液に、メタンスルホニルクロリド(3.5mL)および炭酸カリウム(19g)を加え、4時間撹拌した。反応混合物を水、飽和食塩水で洗浄し、無水硫酸ナトリウムにて乾燥後、溶液が150mL程度になるまで減圧濃縮した。得られた溶液に、ベンジルトリエチルアンモニウムクロリド(14g)およびボロントリフルオリド-エチルエーテルコンプレックス(1.1mL)を加え、30分間撹拌した。反応混合物に水を注ぎ、ジクロロメタンで抽出した。得られた有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムにて乾燥後、減圧濃縮した。得られた残渣をシリカゲルクロマトグラフィー(ヘキサン:酢酸エチル=100:0→80:20)によって精製することにより、以下の物性値を有する標題化合物(5.2g)を得た。
TLC:Rf 0.50 (ヘキサン:酢酸エチル=4:1);
1H-NMR (CDCl3):δ 2.05-2.13, 2.38-2.43, 2.67-2.71, 6.22-6.23。
水素化ナトリウム(550mg)のジエチレングリコールジメチルエーテル(5.0mL)溶液に、2-シアノアセトアミド(1.2g)のジエチレングリコールジメチルエーテル(7.0mL)溶液を加え、20分間撹拌した。実施例37で製造した化合物(1.2g)のジエチレングリコールジメチルエーテル(13mL)溶液を加え、反応混合物を8時間撹拌した。反応混合物を塩酸水溶液中に注ぎ、酢酸エチルで抽出した。得られた有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムにて乾燥後、減圧濃縮することにより、以下の物性値を有する標題化合物(900mg)を得た。
(LC-MS/ELSD):(保持時間:0.49分)。
実施例38で製造した化合物(830mg)のN,N-ジメチルホルムアミド(16mL)溶液に、N,N-ジメチルホルムアミドジメチルアセタール(740μL)を加え、4時間撹拌した。反応混合物に水を加え、酢酸エチルで抽出した。得られた有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムにて乾燥後、減圧濃縮した。得られた残渣を酢酸エチルで洗浄し、ろ取することで、以下の物性値を有する標題化合物(350mg)を得た。
TLC:Rf 0.52(酢酸エチル);
1H-NMR (CD3OD):δ 2.10-2.20, 2.62, 3.08, 8.35。
実施例39で製造した化合物(300mg)のジクロロメタン溶液(12mL)に、フェニルボロン酸(780mg)、4Åモレキュラーシーブ(300mg)、酢酸銅(II)(580mg)、ピリジン(520μL)を加え、一晩撹拌した。反応混合物に、飽和炭酸水素ナトリウム水溶液を加え、ジクロロメタンで抽出した。得られた有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムにて乾燥後、減圧濃縮した。得られた残渣をシリカゲルクロマトグラフィー(ヘキサン:酢酸エチル=50:50→30:70)によって精製することにより、以下の物性値を有する標題化合物(280mg)を得た。
TLC:Rf 0.76(ヘキサン:酢酸エチル=1:9);
1H-NMR (CDCl3):δ 2.15-2.25, 2.66, 3.14, 7.33-7.39, 7.50-7.56, 8.47。
実施例40で製造した化合物(20mg)に、水(0.1mL)および濃硫酸(0.1mL)を加えた。反応混合物を100℃で一晩撹拌した。反応混合物を水酸化ナトリウム水溶液中に注ぎ入れ、酢酸エチルで洗浄した。水層に塩酸水溶液を加え、酢酸エチルで抽出した。得られた有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムにて乾燥後、減圧濃縮することで、以下の物性値を有する標題化合物(6.3mg)を得た。
TLC:Rf 0.68(1-ブタノール:酢酸:水=4:2:1);
1H-NMR (CDCl3):δ 2.10-2.17, 2.66, 3.69, 7.30-7.44, 7.50-7.68, 8.55。
TLC:Rf 0.62 (酢酸エチル:メタノール=19:1);
1H-NMR (CDCl3):δ 2.10-2.20, 2.67, 3.59, 4.06, 6.45, 7.38-7.45, 7.60-7.52, 8.26, 8.42, 8.51, 8.54, 11.53。
実施例41で製造した化合物および実施例2で製造した化合物の代わりに相当するキノリン誘導体を用いて、実施例42と同様の目的の操作に付すことにより、下記物性値を有する標題化合物を得た。
TLC:Rf 0.30 (酢酸エチル);
1H-NMR (CDCl3):δ 2.05-2.25, 2.67, 3.66, 4.05, 4.06, 6.37-6.47, 7.14-7.24, 7.29-7.36, 7.37-7.44, 7.52-7.66, 7.91, 8.49, 8.52, 11.51。
メチル 2-オキソピラン-3-カルボキシラート(CAS登録番号:25991-27-9)(8.4g)および(1S)-1-フェニルエチルアミン(7.9g)をDMF(100mL)に溶解させ、1-(3-ジメチルアミノプロピル)-3-エチルカルボジイミド 塩酸塩(14g)およびN,N-ジメチルピリジン-4-アミン(0.67g)を加えて、室温で16時間撹拌した。反応溶液に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで抽出し、得られた有機層を飽和食塩水で洗浄し、硫酸ナトリウムで乾燥させ、ろ過した後、減圧濃縮することで、下記物性値を有する標題化合物を含む粗生成物(14g)を得た。
TLC:Rf 0.20 (ヘキサン:酢酸エチル=1:1);
1H-NMR (CDCl3):δ 1.73, 3.93, 6.18, 6.53, 7.22-7.41, 8.11。
実施例43で製造した化合物(14g)を用いて、実施例12と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(13g)を得た。
TLC:Rf 0.05 (ヘキサン:酢酸エチル=1:1);
1H-NMR (DMSO-d6):δ 1.78, 6.24, 6.74, 7.26-7.46, 8.24, 8.38, 14.56。
実施例44で製造した化合物(3.0g)をジクロロメタン(12mL)に溶解させ、トリフルオロ酢酸(12mL)およびN-ヨードコハク酸イミド(3.3g)を加えて、室温で12時間撹拌した。反応溶液に水を加えて、ジクロロメタンで抽出し、得られた有機層をチオ硫酸ナトリウムで洗浄し、硫酸ナトリウムで乾燥させ、ろ過した後、減圧濃縮した。得られた残渣をシリカゲルクロマトグラフィー(ヘキサン:酢酸エチル=70:30→50:50)によって精製することにより、以下の物性値を有する標題化合物(3.5mg)を得た。
(LC-MS/ELSD):(保持時間:0.94分);
1H-NMR (CDCl3):δ 1.80, 6.40, 7.32, 7.37-7.47, 7.62, 8.60, 14.14。
実施例45で製造した化合物(2.0g)および実施例2で製造した化合物(1.6mg)を用いて、実施例3と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(3.5g)を得た。
TLC:Rf 0.67 (酢酸エチル);
1H-NMR (CDCl3):δ 1.80, 4.06, 6.47, 6.50, 7.33-7.46, 7.58, 8.32, 8.47, 8.52, 8.70, 12.55。
実施例46で製造した化合物(100mg)をエタノール(4mL)に溶解させ、10%パラジウム-炭素(20mg)を加えて、水素雰囲気下、室温で3時間撹拌した。反応溶液をセライトろ過し、ろ液を減圧濃縮した。得られた残渣をシリカゲルクロマトグラフィー(ヘキサン:酢酸エチル=70:30→0:100)によって精製することにより、以下の物性値を有する標題化合物(30mg)を得た。
TLC:Rf 0.42 (酢酸エチル);
1H-NMR (CDCl3):δ 1.81, 4.07, 6.44, 6.48, 6.59, 7.34-7.47, 7.57, 7.58, 8.33, 8.50, 8.52, 8.59, 12.77。
300mLの3径ナスフラスコにアニリン(3.1g)、4-ジメチルアミノピリジン(0.61g)、トリエチルアミン(5.1mL)、ジクロロメタン(25mL)を加えた後、氷浴下においてエチルマロニルクロライド(5.0g)のジクロロメタン(25mL)溶液を20分かけて滴下した。そのまま30分間撹拌した後、水を加え、ジクロロメタンを減圧留去した。残渣を酢酸エチルで抽出した後、1N塩酸、飽和食塩水の順で洗浄し、無水硫酸ナトリウムで乾燥後、溶媒を減圧留去した。得られた残渣はシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=7:3→1:1)で精製し、下記物性値を有する標題化合物(5.8g)を得た。
TLC:Rf 0.50 (ヘキサン:酢酸エチル=1:1);
1H-NMR (CDCl3):δ 1.32, 3.47, 4.26, 7.13, 7.35, 7.55, 9.22。
200mLのナスフラスコに実施例48で製造した化合物(5.8g)、(E)-4-メトキシ-3-ブテン-2-オン(3.1g)、20% ナトリウムエトキサイドのエタノール溶液(11.4g)、メタノール(30mL)を加えた。16時間加熱還流した後、室温まで放冷し、溶媒を減圧留去した。続いて得られた残渣に2N水酸化ナトリウム水溶液(30mL)、メタノール(30mL)を加えて室温で23時間撹拌させた。反応液に水を加え、酢酸エチルで洗浄した後、5N塩酸で水層をpH=3~4とした。析出した粉末をろ取、乾燥することで下記物性値を有する標題化合物(3.0g)を得た。
TLC:Rf 0.60 (酢酸エチル:メタノール=9:1);
1H-NMR (DMSO-d6):δ 2.15, 6.54, 7.24, 7.63, 8.51, 14.0。
200mLのナスフラスコに実施例49で製造した化合物(2.9g)、メタノール(29mL)、酢酸エチル(29mL)、トリメチルシリルジアゾメタンを加えた。溶媒を減圧留去することで下記物性値を有する標題化合物(2.9g)を得た。
TLC:Rf 0.34 (酢酸エチル);
1H-NMR (CDCl3):δ 2.04, 3.88, 6.22, 7.18, 7.50, 8.20。
100mLのナスフラスコに実施例50で製造した化合物(2g)、N-ブロモスクシンイミド(3.1g)、過酸化ベンゾイル(40mg)、四塩化炭素(36mL)を加えて80℃で6時間加熱した。室温に戻した後、反応液から沈殿物を除去し、溶媒を減圧留去した。得られた残渣を少量の酢酸エチル、ヘキサンで洗浄することで下記物性値を有する標題化合物(2.9g)を得た。
TLC:Rf 0.29 (ヘキサン:酢酸エチル=1:1);
1H-NMR (CDCl3):δ 3.89, 4.14, 7.29, 7.54, 8.33。
100mLのナスフラスコに実施例51で製造した化合物(2.5g)、ジ-tert-ブチル イミドジカルボナート(Boc2NH)(1.6g)、炭酸カリウム(1.7g)、DMF(30mL)を加えた。室温で4時間撹拌した後、飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出し、水、飽和食塩水の順で洗浄後、無水硫酸ナトリウムで乾燥させ、溶媒を減圧留去した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=7:3→1:1)で精製し、下記物性値を有する標題化合物(2.9g)を得た。
TLC:Rf 0.40 (ヘキサン:酢酸エチル=1:1);
1H-NMR (CDCl3):δ 1.40, 3.88, 4.67, 7.20, 7.47, 8.34。
100mLのナスフラスコに実施例52で製造した化合物(2.9g)、2N水酸化ナトリウム水溶液(14mL)、メタノール(14mL)を加えて30分間撹拌させた。反応液に1N塩酸を加え析出した粉末をろ取、乾燥することで下記物性値を有する標題化合物(2.3g)を得た。
TLC:Rf 0.57 (酢酸エチル);
1H-NMR (CDCl3):δ 1.42, 4.69, 7.26, 7.59, 8.67 ,13.77。
実施例53で製造した化合物(530mg)および実施例2で製造した化合物(300mg)を用いて、実施例3と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(770mg)を得た。
TLC:Rf 0.54 (酢酸エチル);
1H-NMR (CDCl3):δ 1.43, 4.07, 4.73, 6.51, 7.28, 7.48, 7.50-7.60, 8.23, 8.47, 8.50, 8.78, 12.25。
実施例54で製造した化合物(100mg)をエタノール(2mL)に溶解させ、10%パラジウム-炭素(100mg)および1mol/L塩酸(0.6mL)を加えて、水素雰囲気下、60℃で3時間撹拌した。原料の消失を確認後、反応溶液をセライトろ過し、ろ液を減圧濃縮した。得られた残渣をメタノール(2mL)に溶解させ、1mol/L塩酸-ジオキサン(0.6mL)を加えて、さらに1時間撹拌した。反応溶液を減圧濃縮し、得られた残渣をプレパラティブ精製(シリカゲルMerck 5744、ジクロロメタン:メタノール:28%アンモニア水=15:1:0.1)することで、下記の物性値を有する標題化合物(47mg)を得た。
TLC:Rf 0.56 (ジクロロメタン:メタノール:アンモニア水=9:1:0.1);
1H-NMR (CDCl3):δ 3.51, 4.05, 6.45, 6.82, 7.25, 7.43, 7.52-7.63, 8.22, 8.47, 8.50, 8.74, 12.36。
実施例55で製造した化合物(45mg)を用いて、実施例36と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(38mg)を得た。
TLC:Rf 0.62 (酢酸エチル:メタノール=9:1);
1H-NMR (CDCl3):δ 1.98, 4.05, 4.08, 6.06, 6.45, 6.60, 7.30, 7.42, 7.52-7.65, 8.22, 8.44, 8.49, 8.68, 12.27。
実施例3で製造した化合物(1.4g)を用いて、実施例45と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(1.3g)を得た。
TLC:Rf 0.50(ヘキサン:酢酸エチル=4:1);
1H-NMR (DMSO-d6):δ 3.90-3.95, 6.54, 7.40、7.51-7.56, 7.85, 8.36, 8.39, 8.44, 8.48, 8.63, 12.30。
実施例57で製造した化合物(500mg)のN,N-ジメチルホルムアミド(5.0mL)溶液に、N-Boc-プロパルギルアミン(220mg)、ヨウ化銅(I)(13mg)、テトラキス(トリフェニルホスフィン)パラジウム(0)(81mg)、N,N-ジイソプロピルエチルアミン(360μL)を加え、アルゴン雰囲気下で一晩撹拌した。反応混合物に水を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルクロマトグラフィー(ヘキサン:酢酸エチル=40:60→20:80)によって精製することにより、以下の物性値を有する標題化合物(430mg)を得た。
TLC:Rf 0.32 (ヘキサン:酢酸エチル=1:4);
1H-NMR (CDCl3):δ 1.47, 4.05, 4.10-4.16, 4.71-4.83, 6.45, 7.37-7.44, 7.50-7.59, 7.81, 8.25, 8.50, 8.70, 12.25。
実施例58で製造した化合物(200mg)を用いて、実施例47と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(200mg)を得た。
TLC:Rf 0.11 (ヘキサン:酢酸エチル=1:4);
1H-NMR (CDCl3):δ 1.44, 1.68-1.93, 2.57, 3.20, 4.06, 4.54-4.65, 6.49, 7.41-7.60, 8.26, 8.47-8.52, 8.63, 12.58。
実施例59で製造した化合物(200mg)を用いて、実施例25と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(150mg)を得た。
TLC:Rf 0.11 (酢酸エチル,NHシリカ);
1H-NMR (CDCl3):δ 1.75-1.88, 2.67, 2.77-2.85, 4.05, 6.46, 7.38-7.59, 8.25, 8.46, 8.50, 8.64, 12.57。
実施例60で製造した化合物(89mg)を用いて、実施例36と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(44mg)を得た。
TLC:Rf 0.68 (酢酸エチル:メタノール=9:1);
1H-NMR (CDCl3):δ 1.85-2.0, 2.50-2.65, 3.34-3.42, 4.05, 5.75-5.87, 6.46, 7.42-7.61, 8.25, 8.46, 8.50, 8.62, 12.56。
室温において1,3-シクロヘキサンジオン(CAS登録番号:504-02-9)(13g)をN,N-ジメチルホルムアミド(DMF)(200mL)に溶解し、tert-ブトキシカリウム(13g)、エチル (E)-2-シアノ-3-エトキシ-2-プロペノエート(CAS登録番号:94-05-3)(20g)を加え、21時間撹拌した。反応溶液を酢酸エチルで希釈し、2Nの塩酸水溶液を加え撹拌した。さらに酢酸エチル、水を加え有機層を抽出した。飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去し、下記物性値を有する標題化合物(24g)を得た。
TLC:Rf 0.35 (ヘキサン:酢酸エチル=1:1);
1H-NMR (CDCl3):δ 1.37, 2.19, 2.61, 2.92, 4.36, 8.63。
室温において実施例62で製造した化合物(10.00g)をエタノール(200mL)に溶解し、アニリン(3.94g)を加え、6時間撹拌した。反応液中から析出した固体を桐山ロートでろ取、エタノールで洗浄し、得られた残渣を60℃で減圧乾燥した。下記物性値を有する標題化合物(4.01g)を得た。
TLC:Rf 0.37 (ジクロロメタン:メタノール=9:1);
1H-NMR (CDCl3):δ 2.11, 2.60, 7.25, 7.63, 9.21。
実施例63で製造した化合物(140mg)と、ヒドロキシルアミン塩酸塩(210mg)のピリジン溶液(1.0mL)を1時間加熱還流した。室温に冷却後、反応液を酢酸エチルで希釈し、1mol/L塩酸で洗浄した。得られた有機層を濃縮し、下記物性値を有する標題化合物(150mg)を得た。
TLC:Rf 0.42 (ジクロロメタン:メタノール=9:1);
1H-NMR (DMSO-d6):δ 1.63-1.81, 2.26-2.36, 2.60, 7.38-7.46, 7.51-7.68, 8.90, 11.30, 14.03。
実施例64で製造した化合物(65mg)と、実施例2で製造した化合物(50mg)を用いて、実施例3と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(59mg)を得た。
TLC: 0.15 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 1.77-1.94, 2.38, 2.77, 4.05, 6.46, 7.20-7.25, 7.43, 7.50-7.65, 7.99-8.07, 8.22, 8.48, 8.52, 9.33, 12.23。
TLC:Rf 0.45 (酢酸エチル:メタノール=10:1,DNHシリカ);
1H-NMR (CDCl3):δ 1.85-2.02, 2.68, 3.23-3.43, 6.23-6.34, 6.44, 7.20-7.25, 7.42, 7.53, 7.55-7.69, 8.21, 8.43-8.52, 9.01, 12.06。
4-ブロモ-2-ニトロベンズアルデヒド(CAS登録番号:5551-12-2)(2.0mg)を無水酢酸(40mL)に溶解させ、マロン酸ジエチル(1.4g)および炭酸カリウム(1.8g)を加えて、80℃で4時間撹拌した。反応溶液を室温まで放冷し、氷冷水にあけ、ジクロロメタンで抽出した。有機層を硫酸ナトリウムで乾燥させ、ろ過した後、減圧濃縮することで、標題化合物を含む粗生成物(3.2g)を得、精製することなく次の反応に用いた。
実施例67で製造した粗生成物(2.8g)を酢酸(24mL)に溶解させ、鉄粉(4.2g)を加えて、80℃で4時間撹拌した。反応溶液をセライトろ過し、ろ液に飽和炭酸水素ナトリウム水溶液を加えて中和し、ジクロロメタンで抽出した。有機層を硫酸ナトリウムで乾燥させ、ろ過した後、減圧濃縮した。得られた残渣をtert-ブチルメチルエーテルで洗浄することで、下記物性値を有する標題化合物(1.2g)を得た。
1H-NMR (CDCl3):δ 1.45, 4.45, 7.34-7.41, 7.48-7.56, 8.50, 10.94。
ジクロロメタン(200mL)に実施例68で製造した化合物(1.2g)、フェニルホウ酸(1.0g)、ジアセトキシ銅(II)(1.5g)、ピリジン(4.0mL)および4Åモレキュラーシーブスを加えて、酸素雰囲気下、室温で64時間撹拌した。反応溶液をセライトろ過し不溶固体を除去した後、ジクロロメタン(200mL)を加えて希釈し、有機層を水洗した。得られた有機層を硫酸ナトリウムで乾燥させ、ろ過した後、減圧濃縮により溶媒を留去した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル 70:30)で精製し、下記物性値を有する標題化合物(0.88g)を得た.
1H-NMR (CDCl3):δ 1.40, 4.41, 6.79-6.82, 7.24-7.25, 7.27-7.29, 7.32-7.38, 7.51-7.66, 8.48。
1,4-ジオキサン(30mL)に実施例69で製造した化合物(800mg)、tert-ブチルカーバメート(380mg)、炭酸セシウム(2.1g)および4,5-ビス(ジフェニルホスフィノ)-9,9-ジメチルキサンテン(150mg)を加えて、窒素置換後、酢酸パラジウム(19mg)を加えて、封管中100℃で3時間撹拌した。反応溶液をセライトろ過し、ろ液を減圧濃縮した。得られた残渣を酢酸エチルで希釈し、水で洗浄し、減圧濃縮で溶媒を留去することで、下記物性値を有する標題化合物(880mg)を得た。
1H-NMR (CDCl3):δ 1.38, 1.43, 4.39, 6.38, 6.66, 7.22-7.25, 7.45-7.65, 8.50。
実施例70で製造した化合物(880mg)を用いて、実施例12と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(650mg)を得た。
1H-NMR (DMSO-d6):δ 1.39, 6.96, 7.38-7.45, 7.52-7.72, 8.00-8.05, 8.94, 9.89, 14.24。
実施例71で製造した化合物(100mg)と、実施例2で製造した化合物(140mg)を用いて、実施例3と同様の目的の操作に付すことにより、下記物性値を有する標題化合物(190mg)を得た。
MS (M+H):660
(LC-MS/ELSD):(保持時間:0.75分);
1H-NMR (CDCl3):δ 4.05, 4.26, 5.80, 6.46, 6.63, 7.30-7.42, 7.54, 7.54-7.66, 8.23, 8.48-8.50, 8.95, 12.44。
実施例2で製造した化合物の代わりに相当するキノリン誘導体、および実施例71で製造した化合物を用いて、実施例3→実施例73と同様の目的の操作に付すことにより、下記の実施例化合物を得た。
実施例73(1):7-アミノ-N-{5-[(7-メトキシ-4-キノリニル)オキシ]-2-ピリジニル}-2-オキソ-1-フェニル-1,2-ジヒドロ-3-キノリンカルボキサミド
(LC-MS/ELSD):(保持時間:0.78分);
1H-NMR (CDCl3):δ 4.01, 4.23, 5.80, 6.54, 6.62, 7.53-7.67, 7.54-7.67, 8.22, 8.29, 8.54, 8.69, 8.95, 12.50。
実施例73(2):7-アミノ-2-オキソ-1-フェニル-N-[5-(4-キノリニルオキシ)-2-ピリジニル]-1,2-ジヒドロ-3-キノリンカルボキサミド
(LC-MS/ELSD):(保持時間:0.76分);
1H-NMR (CDCl3):δ 4.23, 5.80, 6.55, 6.63, 7.30-7.34, 7.53-7.68, 7.74-7.80, 8.10, 8.23, 8.36, 8.51, 8.69, 8.96, 12.45。
以下に生物学的実験例を示し、これらの実験方法に基づいて、本発明化合物の効果を確認した。
Axl酵素阻害活性の測定は、LanthaScreen(登録商標)system(Invitrogen社)により、添付の説明書に準じて実施した。使用した試薬を以下に示した。
反応緩衝液:50mmol/L HEPES(pH7.5)、0.01%Brij35、10mmol/L MgCl2及び1mmol/L EGTAを含む溶液を、精製水を用いて調製した。
被験物質溶液:各濃度の被験化合物のDMSO溶液を反応緩衝液にて20倍希釈し、最終濃度の5倍濃度の被験化合物を含む溶液を調製した。
酵素液:400ng/mL Axl酵素を含む溶液を、反応緩衝液を用いて調製した。
基質液:45μmmol/L ATP及び500nmmol/L Fluorescein-Poly GT(Invitrogen社)を含む溶液を、反応緩衝液を用いて調製した。
検出液:20mM EDTA及び4nM PY20(Invitrogen社)を含む溶液をDilution B(Invitrogen社)を用いて調製した。
生物学的実施例2:Axlを安定発現したマウスプロB細胞株(Ba/F3 Axl)を
用いた増殖抑制率の測定
96ウェルプレートに0.1mmol/Lの被験化合物のDMSO溶液を分注し、さらにDMSOで3倍公比の希釈系列を調製した。各濃度の被験化合物のDMSO溶液をRPMI1640培地(10%HI-FBS、1%ペニシリン含有)でさらに500倍希釈して最終濃度の500倍濃度の被験化合物を含む被験化合物希釈溶液を調製した。測定用の96ウェルプレート(BD Bioscience社)の各ウェルに、Blank群にはRPMI培地を、媒体群には0.2%DMSOを含むRPMI培地を、被験化合物群には被験化合物希釈溶液をそれぞれ50μLずつ添加した。Ba/F3 Axlを、2×105細胞数/mLの密度になるよう培地で希釈し、細胞懸濁液を調製した。測定用の96ウェルプレートの各ウェルに、Blank群にはRPMI培地を、媒体群及び被験化合物群には細胞懸濁液をそれぞれ50μLずつ添加し、37℃、5%CO2で48時間静置した。静置終了後、CELLTITER-GLO(登録商標)LUMINESCENT CELL VIABILITY ASSAY(Promega社)を使用して相対発光単位(RLU;Relative Light Unit)を測定した。測定は添付の説明書に準じて実施した。各ウェルに100μLの発光液を添加し室温にて3分間プレートを撹拌後、室温・遮光下にて10分間静置し、マイクロプレートリーダー(SpectraMax M5e、Molecular Devices社)を用いてRLUを測定した。Blank群及び媒体群のRLUの平均値を算出し、以下の式で被験化合物群の増殖抑制率を算出した。
生物学的実施例1と同様に、被験化合物のKDRキナーゼに対する50%阻害率の値(IC50値)を測定した。被験化合物のKDRに対するAxl選択的な阻害活性は、上記IC50値の比に基づいて算出し、以下の表1に示す通りであった。被験化合物として、本発明化合物は実施例21、実施例42、実施例66、および実施例28を用い、比較化合物は下記構造を有する特許文献5記載の実施例74の化合物(比較化合物B)、および実施例92(比較化合物C)の化合物を用いた。
反応は384ウェルプレート上にて行った。陽性対照物質(CYP2C8:クェルセチン)は最終濃度の300倍の濃度にDMSOで調整し(CYP2C8:22.5および225μmol/L)、2.7%のアセトニトリルを含む精製水で75倍希釈した溶液を準備した(CYP2C8:0.3および3μmol/L)。被験化合物はDMSOで0.3および3mmol/Lに調製後、2.7%アセトニトリルを含む精製水で75倍希釈し、4および40μmol/Lに調製した。次にリン酸カリウム緩衝液(pH7.4)、塩化マグネシウム(5mol/L)、基質(CYP2C8:Luciferin-ME、150μmol/L)および大腸菌発現系肝ミクロソームのCYP2C8(Cypex、30pmol/L)を加えた反応混合液を調製した(数値は最終濃度)。この反応混合液8μLと前述で準備した被験化合物および陽性対照物質溶液を各ウェルに4μL、NADPH産生系溶液(5.2mM NADP、13.2mM グルコース6リン酸、1.6 U/mL グルコース6リン酸デヒドロゲナーゼ)を4μL加えて反応を開始し、37℃で30分間インキュベーションを行った。その後、ルシフェラーゼ溶液 16μLを添加して反応停止とともにルシフェリンを発光させ、反応液の発光強度を測定した。阻害率は被験化合物溶液の代わりにDMSOを添加して反応をおこなったコントロールと比較した時の発光強度の減少率(阻害率)とし、以下の式により算出した。
製剤例1
以下の各成分を常法により混合した後打錠して、一錠中に10mgの活性成分を含有する錠剤1万錠を得た。
・N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-3,8-ジオキソ-2-フェニル-2,3,5,6,7,8-ヘキサヒドロ-4-イソキノリンカルボキサミド…100g
・カルボキシメチルセルロースカルシウム(崩壊剤) … 20g
・ステアリン酸マグネシウム(潤滑剤) … 10g
・微結晶セルロース … 870g
以下の各成分を常法により混合した後、除塵フィルターでろ過し、5mlずつアンプルに充填し、オートクレーブで加熱滅菌して、1アンプル中20mgの活性成分を含有するアンプル1万本を得た。
・N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-3,8-ジオキソ-2-フェニル-2,3,5,6,7,8-ヘキサヒドロ-4-イソキノリンカルボキサミド…200g
・マンニトール … 20g
・蒸留水 … 50L
Claims (15)
- 一般式(I)
ここで、R1で表されるC1~8アルキル基が分枝鎖アルキル基の場合、同一の炭素原子から分枝したC1~3アルキル基は一緒になってC3~7の飽和炭素環を形成してもよく、
R2は(1)1~5個のR21で置換されていてもよいC1~8アルキル基、(2)1~5個のR22で置換されていてもよいC2~8アルケニル基、(3)1~5個のR23で置換されていてもよいC2~8アルキニル基、(4)-OR24基、(5)1~5個のR25で置換されていてもよいC3~7の炭素環、(6)1~5個のR26で置換されていてもよい4~7員のヘテロ環、(7)ハロゲン原子、(8)C(O)R27基、または(9)C(O)NR28R29基を表し、
ここで、mが2以上であり、R2が隣り合う炭素原子上にあり、かつR2がアミノ基で置換されていてもよいC1~3アルキル基、またはアミノ基で置換されていてもよいC2~3アルケニル基を表すとき、隣り合う炭素原子に結合するR2は当該炭素原子と一緒になって、1~3個のR20で置換されていてもよい5~7員の環状基を形成してもよく、このとき、R1がC1~3アルキル基を表すとき、当該複数のR2によって形成された5~7員の環状基上の原子と一緒になって、さらに5~7員の環状基を形成してもよく、
R3は(1)C1~4アルキル基、(2)ハロゲン原子、(3)C1~4ハロアルキル基、または(4)-OR31基を表し、
R4は(1)C1~4アルコキシ基、(2)C1~4ハロアルキル基、(3)-OR41基、(4)C1~4アルキル基、(5)C2~4アルケニルオキシ基、または(6)C2~4アルキニルオキシ基を表し、
R11は(1)-OR101基、(2)SO2R102基、(3)NR103R104基、または(4)1~3個のハロゲン原子で置換されていてもよいC3~7の炭素環を表し、
R12は(1)アミノ基で置換されていてもよいC1~4アルキル基、(2)C1~4ハロアルキル基、(3)ハロゲン原子を表し、
R13は(1)アミノ基で置換されていてもよいC1~4アルキル基、(2)C1~4ハロアルキル基、(3)ハロゲン原子を表し、
R101は(1)水素原子、または(2)C1~4アルキル基を表し、
R102は(1)水素原子、または(2)C1~4アルキル基を表し、
R103およびR104はそれぞれ独立して、(1)水素原子、または(2)C1~4アルキル基を表し、
R20は(1)C1~4アルキル基、(2)ハロゲン原子、(3)C1~4ハロアルキル基、(4)オキソ基、(5)-OR201基、(6)COOR205基、(7)NR206R207基、または(8)COR208基を表し、ここで、2個のR20がC1~3アルキル基を表し、かつ同一の炭素原子上にあるとき、当該R20は一緒になってC3~7の飽和炭素環を形成してもよく、
R21、R22、およびR23はそれぞれ独立して、(1)ハロゲン原子、(2)-OR202基、または(3)NR203R204基を表し、
R24は(1)水素原子、(2)C1~4アルキル基、または(3)4~10員のヘテロ環を表し、
R25およびR26はそれぞれ独立して、(1)C1~4アルキル基、または(2)ハロゲン原子を表し、
R27は(1)水素原子、(2)C1~4アルキル基、または(3)C3~7の炭素環を表し、
R28およびR29はそれぞれ独立して、(1)水素原子、(2)C1~4アルキル基、または(3)C3~7の炭素環を表し、
R201は(1)水素原子、または(2)C1~4アルキル基を表し、
R202は(1)水素原子、または(2)C1~4アルキル基を表し、
R203およびR204はそれぞれ独立して、(1)水素原子、(2)C1~4アルキル基、(3)C(O)R210基、または(4)COOR217基を表し、
R205は(1)水素原子、または(2)C1~4アルキル基を表し、
R206およびR207はそれぞれ独立して、(1)水素原子、または(2)C1~4アルキル基を表し、
R208は(1)水素原子、(2)C1~4アルキル基、(3)C2~4アルケニル基、または(4)C2~4アルキニル基を表し、
R210は(1)NR211R212またはシアノ基で置換されていてもよいC1~4アルキル基、(2)NR213R214またはシアノ基で置換されていてもよいC2~4アルケニル基、または(3)NR215R216またはシアノ基で置換されていてもよいC2~4アルキニル基を表し、
R211、R212、R213、R214、R215、R216およびR217はそれぞれ独立して、(1)水素原子、または(2)C1~4アルキル基を表し、
R31は(1)水素原子、(2)C1~4アルキル基、または(3)C1~4ハロアルキル基を表し、
R41は、(1)水素原子、(2)(a)(i)C1~4アルキル基、(ii)C1~4ハロアルキル基、および(iii)ハロゲン原子からなる群から選択される1~2個の置換基で置換されていてもよい5~7員の環状基、(b)NR401R402、(c)水酸基、および(d)SO2R403基からなる群から選択される1~2個の置換基で置換されたC1~8アルキル基、(3)(a)(i)C1~4アルキル基、(ii)C1~4ハロアルキル基、および(iii)ハロゲン原子からなる群から選択される1~2個の置換基で置換されていてもよい5~7員の環状基、(b)NR401R402、(c)水酸基、および(d)SO2R403基からなる群から選択される1~2個の置換基で置換されたC2~8アルケニル基、または(4)(a)(i)C1~4アルキル基、(ii)C1~4ハロアルキル基、および(iii)ハロゲン原子からなる群から選択される1~2個の置換基で置換されていてもよい5~7員の環状基、(b)NR401R402、(c)水酸基、および(d)SO2R403基からなる群から選択される1~2個の置換基で置換されたC2~8アルキニル基を表し、
R401およびR402はそれぞれ独立して、(1)水素原子、または(2)C1~4アルキル基を表し、
R403は(1)水素原子、または(2)C1~4アルキル基を表し、
Aは(1)CH、または(2)窒素原子を表し、
Lは(1)-O-、(2)-NH-、(3)-C(O)-、(4)-CR6R7-、(5)-S-、(6)-S(O)-、または(7)-S(O)2-を表し、
R6およびR7はそれぞれ独立して、(1)水素原子、(2)ハロゲン原子、(3)C1~4アルキル基、(4)水酸基、または(5)NH2を表し、
ring1は5~7員の環状基を表し、
R11、R12、R13、R20、R21、R22、R23、R25、またはR26は、いずれも複数のとき、同じでも異なっていてもよく、
mは0~3の整数を表し、
nは0~3の整数を表し、
qは0~4の整数を表し、
mが2以上のとき、複数のR2は同じでも異なっていてもよく、
nが2以上のとき、複数のR3は同じでも異なっていてもよく、
qが2以上のとき、複数のR4は同じでも異なっていてもよく、
ただし、式
- R2が(1)1~5個のR21で置換されていてもよいC1~8アルキル基、(2)1~5個のR22で置換されていてもよいC2~8アルケニル基、(3)1~5個のR23で置換されていてもよいC2~8アルキニル基、(4)ハロゲン原子、または(5)C(O)R27基である請求項1記載の化合物。
- ring1がベンゼン、またはピリジンである請求項1~3のいずれかに記載の化合物。
- Lが(1)-O-、(2)-NH-、または(3)-C(O)-である請求項1~4のいずれかに記載の化合物。
- (1)5-アセチル-N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-6-メチル-2-オキソ-1-フェニル-1,2-ジヒドロ-3-ピリジンカルボキサミド、(2)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-3,8-ジオキソ-2-フェニル-2,3,5,6,7,8-ヘキサヒドロ-4-イソキノリンカルボキサミド、(3)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-2,5-ジオキソ-1-フェニル-2,5,6,7,8,9-ヘキサヒドロ-1H-ピリド[3,2-c]アゼピン-3-カルボキサミド、(4)7-アミノ-N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-2-オキソ-1-フェニル-1,2-ジヒドロ-3-キノリンカルボキサミド、(5)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-2-オキソ-1-フェニル-1,2-ジヒドロ-1,7-ナフチリジン-3-カルボキサミド、または(6)7-(2-ブチノイル)-N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-2-オキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-1,7-ナフチリジン-3-カルボキサミドである請求項1記載の化合物。
- 請求項1記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド体、またはそれらのプロドラッグを含有してなる医薬組成物。
- Axl阻害剤である請求項7記載の医薬組成物。
- Axl関連疾患の予防および/または治療剤である請求項7記載の医薬組成物。
- Axl関連疾患が、癌、腎臓疾患、免疫系疾患、または循環器系疾患である請求項9記載の医薬組成物。
- 癌が、急性骨髄性白血病、慢性骨髄性白血病、急性リンパ性白血病、慢性リンパ性白血病、多発性骨髄腫、メラノーマ、乳癌、膵臓癌、神経膠腫、食道腺癌、大腸癌、腎細胞癌、甲状腺癌、非小細胞肺癌、前立腺癌、胃癌、肝癌、ブドウ膜悪性黒色腫、卵巣癌、子宮内膜癌、リンパ腫、頭頸部癌、または肉腫である請求項10記載の医薬組成物。
- 癌細胞の転移抑制剤である請求項7記載の医薬組成物。
- 請求項1記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド、またはそれらのプロドラッグの有効量を哺乳動物に投与することを特徴とする、Axl関連疾患の予防および/または治療方法。
- Axl関連疾患の予防および/または治療のための請求項1記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド、またはそれらのプロドラッグ。
- Axl関連疾患の予防および/または治療剤を製造するための請求項1記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド、またはそれらのプロドラッグの使用。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES15873185T ES2749726T3 (es) | 2014-12-25 | 2015-12-24 | Derivado de quinolina |
US15/539,530 US10208034B2 (en) | 2014-12-25 | 2015-12-24 | Quinoline derivative |
JP2016566451A JP6708130B2 (ja) | 2014-12-25 | 2015-12-24 | キノリン誘導体 |
EP15873185.1A EP3239147B9 (en) | 2014-12-25 | 2015-12-24 | Quinoline derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-262146 | 2014-12-25 | ||
JP2014262146 | 2014-12-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016104617A1 true WO2016104617A1 (ja) | 2016-06-30 |
Family
ID=56150630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/086050 WO2016104617A1 (ja) | 2014-12-25 | 2015-12-24 | キノリン誘導体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10208034B2 (ja) |
EP (1) | EP3239147B9 (ja) |
JP (1) | JP6708130B2 (ja) |
ES (1) | ES2749726T3 (ja) |
WO (1) | WO2016104617A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US10851093B2 (en) * | 2018-06-01 | 2020-12-01 | Rigel Pharmaceuticals, Inc. | Tyrosine kinase inhibitors |
CN112625026A (zh) * | 2019-09-24 | 2021-04-09 | 南京药捷安康生物科技有限公司 | Tam家族激酶抑制剂的喹啉衍生物 |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN112876457A (zh) * | 2021-02-03 | 2021-06-01 | 辽宁大学 | 一种新型4-苯氧基吡啶类衍生物及其应用 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
JP2021524471A (ja) * | 2018-05-21 | 2021-09-13 | 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズShanghai Institute Of Materia Medica, Chinese Academy Of Sciences | 縮合環式ピラゾロンホルムアミド系化合物およびその調製方法、医薬組成物と使用 |
JP2021525270A (ja) * | 2018-05-30 | 2021-09-24 | キュリエント カンパニー, リミテッド | Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体 |
JP2021536436A (ja) * | 2018-08-24 | 2021-12-27 | 南京薬捷安康生物科技有限公司Nanjing Transthera Biosciences Co., Ltd. | キノリン誘導体から調製される新規な阻害剤 |
WO2024022095A1 (zh) * | 2022-07-25 | 2024-02-01 | 上海博悦生物科技有限公司 | Axl&c-Met双重抑制剂、制备方法以及用途 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3845527A4 (en) * | 2018-08-27 | 2022-06-08 | Beijing Yuezhikangtai Biomedicines Co., Ltd. | MULTISUBSTITUTED PYRIDONE DERIVATIVES AND THEIR MEDICAL USE |
CN110330479A (zh) * | 2019-07-19 | 2019-10-15 | 南京华威医药科技集团有限公司 | 一种用作axl抑制剂的抗肿瘤化合物及其用途 |
WO2021025407A1 (ko) * | 2019-08-02 | 2021-02-11 | 웰마커바이오 주식회사 | 옥소-피리딘 융합고리 유도체 및 이를 포함하는 약학적 조성물 |
JP2023514725A (ja) * | 2020-02-24 | 2023-04-07 | エグゼリクシス, インコーポレイテッド | 化合物および使用方法 |
TW202144333A (zh) * | 2020-03-30 | 2021-12-01 | 大陸商和記黃埔醫藥(上海)有限公司 | 醯胺類化合物及其用途 |
WO2022178205A1 (en) * | 2021-02-19 | 2022-08-25 | Exelixis, Inc. | Pyridone compounds and methods of use |
CN115073367A (zh) * | 2021-03-16 | 2022-09-20 | 南京科默生物医药有限公司 | 一种用作axl抑制剂的抗肿瘤化合物及其用途 |
CN117412953A (zh) * | 2021-05-12 | 2024-01-16 | 微境生物医药科技(上海)有限公司 | Axl抑制剂 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007033196A1 (en) * | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
JP2008539275A (ja) * | 2005-04-27 | 2008-11-13 | アムジエン・インコーポレーテツド | タンパク質キナーゼ阻害薬としての置換アミド誘導体 |
JP2009537632A (ja) * | 2006-05-19 | 2009-10-29 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 過剰増殖性障害および血管新生障害の処置に有用なピリドンカルボキサミド誘導体 |
JP2009539878A (ja) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
JP2010178651A (ja) * | 2009-02-04 | 2010-08-19 | Eisai R & D Management Co Ltd | Hgfr阻害物質の作用検定方法 |
JP2011517689A (ja) * | 2008-04-16 | 2011-06-16 | マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー | Axlキナーゼ阻害剤としてのキノリン誘導体 |
JP2014533287A (ja) * | 2011-11-14 | 2014-12-11 | セファロン、インク. | AXLおよびc−METキナーゼ阻害剤としてのウラシル誘導体 |
WO2015012298A1 (ja) * | 2013-07-24 | 2015-01-29 | 小野薬品工業株式会社 | キノリン誘導体 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
JP5699075B2 (ja) | 2008-05-14 | 2015-04-08 | アムジエン・インコーポレーテツド | 癌の治療のためのvegf(r)阻害剤および肝細胞増殖因子(c−met)阻害剤との組合せ |
EP2349328A1 (en) * | 2008-10-01 | 2011-08-03 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
JP5525612B2 (ja) | 2010-07-23 | 2014-06-18 | 国立大学法人 東京大学 | 含窒素複素環誘導体 |
EP2423208A1 (en) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
CN103298460B (zh) | 2010-12-14 | 2016-06-01 | 电泳有限公司 | 酪蛋白激酶1δ(CK1δ)抑制剂 |
CN102816175B (zh) * | 2011-06-09 | 2015-12-16 | 上海汇伦生命科技有限公司 | 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途 |
-
2015
- 2015-12-24 EP EP15873185.1A patent/EP3239147B9/en active Active
- 2015-12-24 JP JP2016566451A patent/JP6708130B2/ja active Active
- 2015-12-24 ES ES15873185T patent/ES2749726T3/es active Active
- 2015-12-24 US US15/539,530 patent/US10208034B2/en active Active
- 2015-12-24 WO PCT/JP2015/086050 patent/WO2016104617A1/ja active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008539275A (ja) * | 2005-04-27 | 2008-11-13 | アムジエン・インコーポレーテツド | タンパク質キナーゼ阻害薬としての置換アミド誘導体 |
WO2007033196A1 (en) * | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
JP2009537632A (ja) * | 2006-05-19 | 2009-10-29 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 過剰増殖性障害および血管新生障害の処置に有用なピリドンカルボキサミド誘導体 |
JP2009539878A (ja) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
JP2011517689A (ja) * | 2008-04-16 | 2011-06-16 | マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー | Axlキナーゼ阻害剤としてのキノリン誘導体 |
JP2010178651A (ja) * | 2009-02-04 | 2010-08-19 | Eisai R & D Management Co Ltd | Hgfr阻害物質の作用検定方法 |
JP2014533287A (ja) * | 2011-11-14 | 2014-12-11 | セファロン、インク. | AXLおよびc−METキナーゼ阻害剤としてのウラシル誘導体 |
WO2015012298A1 (ja) * | 2013-07-24 | 2015-01-29 | 小野薬品工業株式会社 | キノリン誘導体 |
Non-Patent Citations (2)
Title |
---|
LOVERING,F. ET AL.: "Identification of type-II inhibitors using kinase structures", CHEMICAL BIOLOGY & DRUG DESIGN, vol. 80, no. 5, 2012, pages 657 - 664, XP055394475 * |
ZHANG,W. ET AL.: "Discovery of novel type II c- Met inhibitors based on BMS-777607", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 80, June 2014 (2014-06-01), pages 254 - 266, XP055394473 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7339282B2 (ja) | 2018-05-21 | 2023-09-05 | 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ | 縮合環式ピラゾロンホルムアミド系化合物およびその調製方法、医薬組成物と使用 |
JP2021524471A (ja) * | 2018-05-21 | 2021-09-13 | 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズShanghai Institute Of Materia Medica, Chinese Academy Of Sciences | 縮合環式ピラゾロンホルムアミド系化合物およびその調製方法、医薬組成物と使用 |
JP2021525270A (ja) * | 2018-05-30 | 2021-09-24 | キュリエント カンパニー, リミテッド | Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体 |
JP7390313B2 (ja) | 2018-05-30 | 2023-12-01 | キュリエント カンパニー, リミテッド | Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体 |
US10851093B2 (en) * | 2018-06-01 | 2020-12-01 | Rigel Pharmaceuticals, Inc. | Tyrosine kinase inhibitors |
JP2021536436A (ja) * | 2018-08-24 | 2021-12-27 | 南京薬捷安康生物科技有限公司Nanjing Transthera Biosciences Co., Ltd. | キノリン誘導体から調製される新規な阻害剤 |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
CN112625026B (zh) * | 2019-09-24 | 2022-09-09 | 药捷安康(南京)科技股份有限公司 | Tam家族激酶抑制剂的喹啉衍生物 |
CN112625026A (zh) * | 2019-09-24 | 2021-04-09 | 南京药捷安康生物科技有限公司 | Tam家族激酶抑制剂的喹啉衍生物 |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN112876457A (zh) * | 2021-02-03 | 2021-06-01 | 辽宁大学 | 一种新型4-苯氧基吡啶类衍生物及其应用 |
WO2024022095A1 (zh) * | 2022-07-25 | 2024-02-01 | 上海博悦生物科技有限公司 | Axl&c-Met双重抑制剂、制备方法以及用途 |
Also Published As
Publication number | Publication date |
---|---|
JP6708130B2 (ja) | 2020-06-10 |
US20170349583A1 (en) | 2017-12-07 |
US10208034B2 (en) | 2019-02-19 |
JPWO2016104617A1 (ja) | 2017-10-05 |
EP3239147B9 (en) | 2020-01-08 |
EP3239147A4 (en) | 2017-12-13 |
ES2749726T3 (es) | 2020-03-23 |
EP3239147A1 (en) | 2017-11-01 |
EP3239147B1 (en) | 2019-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6708130B2 (ja) | キノリン誘導体 | |
JP6436205B2 (ja) | キノリン誘導体 | |
JP6493218B2 (ja) | ピロロピリミジン誘導体 | |
WO2012005227A1 (ja) | テトラヒドロカルボリン誘導体 | |
JP2013129632A (ja) | Enpp2阻害化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15873185 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016566451 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015873185 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15539530 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |